{"id":16578,"date":"2024-02-26T17:10:57","date_gmt":"2024-02-26T08:10:57","guid":{"rendered":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/?page_id=16578"},"modified":"2026-01-08T15:21:30","modified_gmt":"2026-01-08T06:21:30","slug":"results","status":"publish","type":"page","link":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/department\/shinryoka\/syounai\/results\/","title":{"rendered":"\u6d88\u5316\u5668\u5185\u79d1\u3000\u81e8\u5e8a\u7814\u7a76\u767a\u8868\u5b9f\u7e3e"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">\u5e73\u621028\u5e74\u5ea6\uff5e\u4ee4\u548c6\u5e74\u5ea6<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c6\u5e74\u5ea6<\/h3>\n\n\n\n<p><strong>\u3010\u8ad6\u6587\u3011<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u8352\u6728\u771e\u88d5. \u76f4\u63a5\u578b\u6297\u30a6\u30a4\u30eb\u30b9\u85ac\u6cbb\u7642\u6642\u4ee3\u306eC\u578b\u809d\u708e\u60a3\u8005\u306e\u9662\u5916\u62fe\u3044\u4e0a\u3052.\u809d\u81d3\u300065(5);214-222\u30012024<\/li>\n<\/ol>\n\n\n\n<p><strong>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u4e2d\u897f\u9999\u4f01\u3001\u77f3\u795e\u6d69\u5fb3\u3001\u5927\u68ee\u5065\u3001\u5c0f\u5bfa\u6cf0\u5f18\u3001\u85ae\u5d0e\u88d5\u3001\u6df1\u5ddd\u525b\u751f\u3001\u4eca\u91ce\u5143\u535a\u3001\u9580\u8107\u91cd\u61b2\u3001\u51a8\u7530\u5bff\u5f66\u3001\u79c0\u6751\u6643\u751f\u3001\u6709\u4e0a\u8cb4\u660e\u3001\u5ee3\u91ce\u5eb7\u592b\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u68ee\u7530\u52dd\u3001\u8fbb\u9756\u3001\u6960\u672c\u54f2\u4e5f\u3001\u6587\u6b63\u6d69\u3001\u6728\u4e0b\u6df3\u3001\u5c71\u53e3\u535a\u7d00\u3001\u5317\u5c71\u4e08\u4e8c. \u80c3\u764c\u8179\u819c\u64ad\u7a2e\u306b\u5bfe\u3059\u308b\u5168\u8eab\u30fb\u8179\u8154\u5185\u6295\u4e0e\u4f75\u7528\u5316\u5b66\u7642\u6cd5. \u7b2c124\u56de\u65e5\u672c\u5916\u79d1\u5b66\u4f1a\u5b9a\u671f\u5b66\u8853\u96c6\u4f1a. 2024.4\uff08\u5e38\u6ed1\uff09<\/li>\n\n\n\n<li>\u5927\u95a2\u745e\u6cbb\u3001\u5c71\u53e3\u53f3\u771f\u3001\u702c\u5c71\u4f91\u4eae\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u5c71\u5ca1\u6b63\u6cbb,\u3001\u4e94\u982d\u4e09\u79c0\u3001 \u8352\u6728\u771e\u88d5\u3001\u5929\u8c9d\u8ce2\u4e8c. \u5f53\u9662\u306e\u80c6\u7ba1\u6df1\u90e8\u633f\u7ba1\u56f0\u96e3\u4f8b\u306b\u304a\u3051\u308b\u30d7\u30ec\u30ab\u30c3\u30c8\u306e\u691c\u8a0e.\u7b2c107\u56de\u65e5\u672c\u6d88\u5316\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u7dcf\u4f1a. 2024.5\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5\u3001\u702c\u5c71\u4f91\u4eae\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u5c71\u5ca1\u6b63\u6cbb. \u7d4c\u53e3\u5264\u6cbb\u7642\u6642\u4ee3\u306eC\u578b\u809d\u708e\u60a3\u8005\u306e\u9662\u5916\u62fe\u3044\u4e0a\u3052. \u7b2c60\u56de\u65e5\u672c\u809d\u81d3\u5b66\u4f1a\u7dcf\u4f1a. 2024.6(\u718a\u672c)<\/li>\n\n\n\n<li>\u7b39\u4e95\u88d5\u5e73\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u702c\u5c71\u4f91\u4eae\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u5927\u95a2\u745e\u6cbb\u3001\u4e94\u982d\u4e09\u79c0\u3001\u8352\u6728\u771e\u88d5. \u7d4c\u809b\u9580\u30a4\u30ec\u30a6\u30b9\u7ba1\u306b\u3088\u308b\u6301\u7d9a\u6e1b\u5727\u3068\u8178\u7ba1\u6d17\u6d44\u306b\u3088\u308a\u6551\u547d\u3057\u5f97\u305f\u5287\u75c7\u578bCDI\u306e1\u4f8b. \u7b2c381\u56de\u65e5\u672c\u6d88\u5316\u5668\u75c5\u5b66\u4f1a\u95a2\u6771\u652f\u90e8\u4f8b\u4f1a. 2024.9\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>\u702c\u5c3e\u76f4\u7f8e\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u7530\u5d0e\u7f8e\u7d00\u3001\u6fa4\u4f73\u5b5d\u3001\u9ad8\u6816\u5b8f\u7f8e\u3001\u5ca1\u7530\u8cb4\u88d5\u3001\u6e05\u5d8b\u8b77\u4e4b.\u5165\u9662\u30b5\u30dd\u30fc\u30c8\u30bb\u30f3\u30bf\u30fc\u4ecb\u5165\u306b\u3088\u308b\u30bf\u30b9\u30af\u30b7\u30d5\u30c8\u306e\u53d6\u308a\u7d44\u307f. \u7b2c24\u56de\u65e5\u672c\u30af\u30ea\u30cb\u30ab\u30eb\u30d1\u30b9\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a. 2024.10\uff08\u677e\u5c71\uff09<\/li>\n\n\n\n<li>\u77f3\u4e95\u4f38\u5c1a\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u7530\u53e3\u771f\u5e0c\u3001\u5ca1\u7530\u8cb4\u88d5\u3001\u5965\u91ce\u8cb4\u4e4b\u3001\u6e05\u5d8b\u8b77\u4e4b. DPC\u30c7\u30fc\u30bf\u3068\u30d0\u30ea\u30a2\u30f3\u30b9\u5206\u6790\u306b\u3088\u308b\u30d1\u30b9\u306b\u304a\u3051\u308b\u30ea\u30cf\u30d3\u30ea\u306e\u691c\u8a0e. \u7b2c24\u56de\u65e5\u672c\u30af\u30ea\u30cb\u30ab\u30eb\u30d1\u30b9\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a. 2024.10\uff08\u677e\u5c71\uff09<\/li>\n\n\n\n<li>\u5c71\u5ca1\u6b63\u6cbb\u3001\u6fa4\u4f73\u5b5d\u3001\u702c\u5c3e\u76f4\u7f8e\u3001\u9ad8\u6816\u5b8f\u7f8e\u3001\u5ca1\u7530\u8cb4\u88d5\u3001\u6e05\u5d8b\u8b77\u4e4b. ERCP\u30d1\u30b9\u306e\u30d0\u30ea\u30a2\u30f3\u30b9\u5206\u6790\u3068\u6539\u8a02\u3000\u6297\u751f\u5264\u9069\u6b63\u4f7f\u7528\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u7b2c24\u56de\u65e5\u672c\u30af\u30ea\u30cb\u30ab\u30eb\u30d1\u30b9\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a. 2024.10\uff08\u677e\u5c71\uff09<\/li>\n\n\n\n<li>\u6fa4\u4f73\u5b5d\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u702c\u5c3e\u76f4\u7f8e\u3001\u9ad8\u6816\u5b8f\u7f8e\u3001\u5916\u585a\u6075\u7406\u5b50\u3001\u5ca1\u7530\u8cb4\u88d5\u3001\u6e05\u5d8b\u8b77\u4e4b. ERCP\u30d1\u30b9\u306e\u30d0\u30ea\u30a2\u30f3\u30b9\u5206\u6790\u3068\u6539\u8a02\u3000\u770b\u8b77\u5e2b\u306b\u3088\u308b\u691c\u8a0e. \u7b2c24\u56de\u65e5\u672c\u30af\u30ea\u30cb\u30ab\u30eb\u30d1\u30b9\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a. 2024.10\uff08\u677e\u5c71\uff09<\/li>\n\n\n\n<li>\u9ad8\u6816\u5b8f\u7f8e\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u6e21\u908a\u7406\u6075\u3001\u8c4a\u5d0e\u7531\u82b1\u3001\u702c\u5c3e\u76f4\u7f8e\u3001\u5ca1\u7530\u8cb4\u88d5\u3001\u6e05\u5d8b\u8b77\u4e4b.\u30a2\u30f3\u30b1\u30fc\u30c8\u304b\u3089\u898b\u305fCOVID-19\u30af\u30ea\u30cb\u30ab\u30eb\u30d1\u30b9\u306e\u6709\u7528\u6027. \u7b2c24\u56de\u65e5\u672c\u30af\u30ea\u30cb\u30ab\u30eb\u30d1\u30b9\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a. 2024.10\uff08\u677e\u5c71\uff09<\/li>\n\n\n\n<li>\u767d\u571f\u512a\u5b50\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u6d77\u8001\u6fa4\u667a\u6075\u3001\u9ad8\u6816\u5b8f\u7f8e\u3001\u5916\u585a\u6075\u7406\u5b50\u3001\u5ca1\u7530\u8cb4\u88d5\u3001\u5965\u91ce\u8cb4\u4e4b\u3001\u6e05\u5d8b\u8b77\u4e4b. \u770b\u8b77\u5e2b\u306e\u8996\u70b9\u306b\u3088\u308b\u5927\u8178\u5207\u9664\u30d1\u30b9\u306e\u30d0\u30ea\u30a2\u30f3\u30b9\u5206\u6790\u3068\u6539\u8a02. \u7b2c24\u56de\u65e5\u672c\u30af\u30ea\u30cb\u30ab\u30eb\u30d1\u30b9\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a. 2024.10\uff08\u677e\u5c71\uff09<\/li>\n\n\n\n<li>\u5c71\u5ca1\u6b63\u6cbb\u3001\u4e94\u982d\u4e09\u79c0\u3001\u702c\u5c71\u4f91\u4eae\u3001\u6749\u5c71\u6cbb\u4e45\u3001\u5c71\u53e3\u53f3\u771f\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u83c5\u8c37\u660e\u5fb3\u3001\u5927\u95a2\u745e\u6cbb\u3001\u8352\u6728\u771e\u88d5\u3001\u5929\u8c9d\u8ce2\u4e8c. 10mm\u4ee5\u4e0b\u306e\u65e9\u671f\u5927\u8178\u764c\u3068\u9ad8\u7570\u578b\u5ea6\u817a\u816b\u306e\u5185\u8996\u93e1\u7684\u6cbb\u7642\u72b6\u6cc1. \u7b2c108\u56de\u65e5\u672c\u6d88\u5316\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u7dcf\u4f1a. 2024.10\uff08\u795e\u6238\uff09<\/li>\n\n\n\n<li>\u702c\u5c71\u4f91\u4eae\u3001\u6749\u5c71\u6cbb\u4e45\u3001\u5c71\u53e3\u53f3\u771f\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u83c5\u8c37\u660e\u5fb3\u3001\u5927\u95a2\u745e\u6cbb\u3001\u8352\u6728\u771e\u88d5\u3001\u4e94\u982d\u4e09\u79c0\u3001\u5929\u8c9d\u8ce2\u4e8c. \u6d88\u5316\u7ba1\u7570\u7269\u306b\u304a\u3051\u308b\u5185\u8996\u93e1\u7684\u7570\u7269\u9664\u53bb\u8853\u306e\u6709\u52b9\u6027\u306e\u691c\u8a0e. \u7b2c108\u56de\u65e5\u672c\u6d88\u5316\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u7dcf\u4f1a. 2024.10\uff08\u795e\u6238\uff09<\/li>\n\n\n\n<li>\u7a32\u57a3\u5343\u6676\u3001\u50b3\u7530\u5fe0\u9053\u3001\u5c0f\u8c37\u5927\u8f14\u3001\u4e95\u4e0a\u6c38\u4ecb\u3001\u67cf\u7530\u77e5\u7f8e\u3001\u4e09\u539f\u826f\u660e\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u8acf\u8a2a\u96c4\u4eae\u3001\u592a\u7530\u9ad8\u5fd7\u3001\u7d50\u57ce\u654f\u5fd7\u3001\u5869\u6fa4\u5b66\u3001\u8fbb\u6643\u4ec1\u3001\u5ba4\u572d\u3001\u5e02\u5ddd\u5ea6\u3001\u7802\u5ddd\u512a. BRAF\u5909\u7570\u578b\u8ee2\u79fb\u6027\u5927\u8178\u764c\u60a3\u8005\u306b\u5bfe\u3059\u308bBRAF\u963b\u5bb3\u5264\u4f75\u7528\u7642\u6cd5\u306e\u89b3\u5bdf\u7814\u7a76\u3000BEETS\u8a66\u9a13(JACCRO CC-18)\u304b\u3089\u306e\u30ea\u30a2\u30eb\u30ef\u30fc\u30eb\u30c9\u30a8\u30d3\u30c7\u30f3\u30b9(An Observational Study of BRAF Inhibitor Combination Therapy for BRAF-mutated Metastatic Colorectal Cancer Patients: Real-World Evidence from BEETS Trial(JACCRO CC-18). \u7b2c62\u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a 2024.10\uff08\u798f\u5ca1\uff09<\/li>\n<\/ol>\n\n\n\n<p><strong>\u3010\u8b1b\u6f14\u3011<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u8352\u6728\u771e\u88d5. HCV 2024\u3000\u301cC\u578b\u809d\u708e\u306e\u3053\u308c\u307e\u3067\u3068\u3053\u308c\u304b\u3089\u301c.\u3000\u7b2c41\u56de\u65e5\u672c\u547c\u5438\u5668\u5916\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a \u30a2\u30d5\u30bf\u30cc\u30fc\u30f3\u30bb\u30df\u30ca\u30fc\u30012024.6 (\u8efd\u4e95\u6ca2)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. \u6162\u6027\u809d\u81d3\u75c5 \u6700\u8fd1\u306e\u30c8\u30d4\u30c3\u30af\u30b9\u3000\u301cC\u578b\u809d\u708e\u3092\u4e2d\u5fc3\u306b\u301c. \u77f3\u5ca1\u5e02\u533b\u5e2b\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\u30012024.6 (\u77f3\u5ca1)<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c. \u304c\u3093\u8a3a\u7642\u306b\u3064\u3044\u3066\uff08\u8a3a\u65ad\u30fb\u6cbb\u7642\u30fb\u7de9\u548c\u30b1\u30a2\uff09. \u6c34\u6238\u5e02\u7acb\u5185\u539f\u56f3\u66f8\u9928\u3000\u56f3\u66f8\u9928\u3067\u533b\u7642\u8b1b\u5ea7\u30012024.9\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c. \u304c\u3093\u306e\u6700\u65b0\u533b\u7642\u3068\u691c\u8a3a\u306b\u3064\u3044\u3066. \u8328\u57ce\u770c\u7acb\u56f3\u66f8\u9928\u3000\u77e5\u306e\u63a2\u6c42\u30bb\u30df\u30ca\u30fc\u30012024.10\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. \u300e\u76f4\u63a5\u578b\u6297\u30a6\u30a4\u30eb\u30b9\u85ac\u6cbb\u7642\u6642\u4ee3\u306eC\u578b\u809d\u708e\u60a3\u8005\u306e\u9662\u5916\u62fe\u3044\u4e0a\u3052\u300f\u3068\u305d\u306e\u3086\u304f\u3048. \u7b2c14\u56de\u9996\u90fd\u570fLiver Forum\u30012024.10\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. \u300c\u76f4\u63a5\u578b\u6297\u30a6\u30a4\u30eb\u30b9\u85ac\u6cbb\u7642\u6642\u4ee3\u306eC\u578b\u809d\u708e\u60a3\u8005\u306e\u9662\u5916\u62fe\u3044\u4e0a\u3052\u300d\u3068\u305d\u306e\u5c55\u958b. HCV Forum in Tsukuba\u30012024.11\uff08\u3064\u304f\u3070\uff09<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. C\u578b\u809d\u708e\u306e\u3053\u308c\u307e\u3067\u3068\u3053\u308c\u304b\u3089.\u3000\u7b2c41\u56de\u8328\u57ce\u770c\u81e8\u5e8a\u691c\u67fb\u5b66\u4f1a \u30e9\u30f3\u30c1\u30e7\u30f3\u30bb\u30df\u30ca\u30fc\u30012024.11 (\u3064\u304f\u3070)<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c. \u9ad8\u6821\u751f\u304b\u3089\u8003\u3048\u308b\u304c\u3093\u306e\u4e88\u9632.\u3000\u8328\u57ce\u770c\u7acb\u90a3\u73c2\u6e4a\u9ad8\u7b49\u5b66\u6821 \u304c\u3093\u6559\u80b2\u8b1b\u8a71\u30012024.11\uff08\u3072\u305f\u3061\u306a\u304b\uff09<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c. \u4e2d\u5b66\u751f\u304b\u3089\u8003\u3048\u308b\u304c\u3093\u4e88\u9632.\u3000\u6c34\u6238\u5e02\u7acb\u98ef\u5bcc\u4e2d\u5b66\u6821 \u304c\u3093\u4e88\u9632\u6559\u80b2\u8b1b\u6f14\u4f1a\u30012024.11\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c. \u4e2d\u5b66\u751f\u304b\u3089\u8003\u3048\u308b\u304c\u3093\u4e88\u9632.\u3000\u7b20\u9593\u5e02\u7acb\u53cb\u90e8\u4e2d\u5b66\u6821 \u304c\u3093\u4e88\u9632\u6559\u80b2\u8b1b\u6f14\u4f1a\u30012024.12\uff08\u7b20\u9593\uff09<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. \u300cABC\u6cd5\u300d\u306b\u3088\u308bC\u578b\u809d\u708e\u60a3\u8005\u306e\u9662\u5916\u62fe\u3044\u4e0a\u3052\u3000-\u6614\u8a71\u3092\u305d\u3048\u3066-.\u3000\u770c\u5357\u770c\u897f\u809d\u75be\u60a3\u7814\u7a76\u4f1a \u6559\u80b2\u8b1b\u6f14\u30012025.2(\u3064\u304f\u3070)<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c5\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8457\u66f8\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Satake H\u3001 Lee KW\u3001 Chung HC\u3001 Lee J\u3001 Yamaguchi K\u3001 Chen JS\u3001 Yoshikawa T\u3001 Amagai K\u3001 Yeh KH\u3001 Goto M\u3001 Chao Y\u3001 Lam KO\u3001 Han SR\u3001 Shiratori S\u3001 Shah S\u3001 Shitara K. Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062. Jpn J Clin Oncol. 53(3):221-229\u30012023<\/li>\n\n\n\n<li>Muro K\u3001 Shitara K\u3001 Yamaguchi K\u3001 Yoshikawa T\u3001 Satake H\u3001 Hara H\u3001 Sugimoto N\u3001 Machida N\u3001 Goto M\u3001 Kawakami H\u3001 Amagai K\u3001 Omuro Y\u3001 Esaki T\u3001 Hironaka S\u3001 Nishina T\u3001 Komatsu Y\u3001 Matsubara H\u3001 Shiratori S\u3001 Han S\u3001 Satoh T\u3001 Ohtsu A. Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer. J Gastrointest Cancer. 54(3):951-961\u30012023<\/li>\n\n\n\n<li>Imai H\u3001 Sakamoto Y\u3001 Takahashi S\u3001 Shibata H\u3001 Sato A\u3001 Otsuka K\u3001 Amagai K\u3001 Takahashi M\u3001 Yamaguchi T\u3001 Ishioka C. Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: study protocol for a multicenter\u3001 randomized phase 2 trial (T-CORE2201). BMC Cancer. 24(1):262 \u30012024<\/li>\n\n\n\n<li>\u5c71\u5ca1\u6b63\u6cbb\u3001\u79cb\u6839\u5927\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u77f3\u4e95\u88d5\u7f8e\u5b50\u3001\u6e21\u908a\u7406\u6075\u3001\u9ad8\u6816\u5b8f\u7f8e\u3001\u5ca1\u7530\u8cb4\u88d5\u3001\u5883\u9054\u90ce\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u5ddd\u5d0e\u666e\u53f8\u3001\u6b66\u5b89\u6cd5\u4e4b\u3001\u6e05\u5d8b\u8b77\u4e4b\uff0e\u5f53\u9662\u306eCOVID-19\u5165\u9662\u8a3a\u7642\u306b\u304a\u3051\u308b\u30af\u30ea\u30cb\u30ab\u30eb\u30d1\u30b9\u306e\u6709\u7528\u6027\uff0e\u8328\u57ce\u770c\u7acb\u75c5\u9662\u533b\u5b66\u96d1\u8a8c40(1);19-28\u30012023<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c4\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Moriwaki T, Nishina T, Sakai Y, Yamamoto Y, Shimada M, Ishida H, Amagai K, Sato M, Endo S, Negoro Y, Kuramochi H, Denda T, Hatachi Y, Ikezawa K, Nakajima G, Bando Y, Tsuji A, Yamamoto Y, Morimoto M, Kobayashi K, Hyodo I. Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged &gt;75 years. Jpn J Clin Oncol. 52(7):725-734\u30012022<\/li>\n\n\n\n<li>Yamaguchi K, Minashi K, Sakai D, Nishina T, Omuro Y, Tsuda M, Iwagami S, Kawakami H, Esaki T, Sugimoto N, Oshima T, Kato K, Amagai K, Hosaka H, Komine K, Yasui H, Negoro Y, Ishido K, Tsushima T, Han S, Shiratori S, Takami T, Shitara K. Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer. Cancer Sci. 113(8):2814-2827\u30012022<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. \u5c02\u9580\u533b\u306e\u76f4\u63a5\u4ecb\u5165\u306b\u3088\u308b\u5185\u670d\u85ac\u306a\u3069\u306eB\u578b\u809d\u708e\u518d\u6d3b\u6027\u5316\u4e88\u9632\u306e\u305f\u3081\u306e\u30ea\u30b9\u30af\u30de\u30cd\u30b8\u30e1\u30f3\u30c8. \u809d\u81d3\u300063(10);445-455\u30012022<\/li>\n\n\n\n<li>\u77e2\u53e3\u671b\u3001\u658e\u85e4\u5c0f\u5f13\u3001\u65e5\u5409\u96c5\u4e5f\u3001\u4e94\u982d\u4e09\u79c0\u3001\u72e9\u91ce\u4fca\u5e78. \u75d4\u763b\u764c\u306e1\u4f8b. \u76ae\u819a\u79d1\u306e\u81e8\u5e8a\u300065\uff083\uff09\u30012023<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u5927\u95a2\u745e\u6cbb\u3001\u771f\u4e0b\u7fd4\u592a\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u4e94\u982d\u4e09\u79c0\u3001\u8352\u6728\u771e\u88d5\u3001\u5929\u8c9d\u8ce2\u4e8c. \u80c6\u9053\u30d6\u30e9\u30b7\u7d30\u80de\u8a3a\u30fb\u751f\u691c\u9257\u5b50\u7d44\u7e54\u8a3a\u306e\u6709\u52b9\u6027\u3068\u5b89\u5168\u6027. \u7b2c103\u56de\u65e5\u672c\u6d88\u5316\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u7dcf\u4f1a. 2022.5(\u4eac\u90fd)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. \u5c02\u9580\u533b\u306e\u76f4\u63a5\u4ecb\u5165\u306b\u3088\u308b\u5185\u670d\u85ac\u306a\u3069\u306eB\u578b\u809d\u708e\u518d\u6d3b\u6027\u5316\u4e88\u9632\u306e\u305f\u3081\u306e\u9662\u5185\u62fe\u3044\u4e0a\u3052. \u7b2c58\u56de\u809d\u81d3\u5b66\u4f1a\u7dcf\u4f1a. 2022.6(\u6a2a\u6d5c)<\/li>\n\n\n\n<li>\u65e5\u91ce\u96c5\u4e88\u3001\u7530\u6751\u667a\u5b8f\u3001\u81fc\u4e95\u4fca\u660e\u3001\u79cb\u5c71\u7a1c\u4ecb\u3001\u8352\u6728\u771e\u88d5\u3001\u5c0f\u6797\u5f18\u660e. \u30c7\u30e5\u30eb\u30d0\u30eb\u30de\u30d6\u306b\u3088\u308b\u514d\u75ab\u95a2\u9023\u6709\u5bb3\u4e8b\u8c61\u3067\u6025\u6027\u809d\u4e0d\u5168\u3092\u767a\u75c7\u3057\u3001\u8840\u6f3f\u4ea4\u63db\u3092\u884c\u3063\u305f\u304c\u6551\u547d\u3067\u304d\u306a\u304b\u3063\u305f68\u6b73\u7537\u6027. \u7b2c67\u56de\u65e5\u672c\u900f\u6790\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a. 2022.7(\u6a2a\u6d5c)<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c.\u982d\u9838\u90e8\u30ad\u30e3\u30f3\u30b5\u30fc\u30dc\u30fc\u30c9\u306b\u304a\u3051\u308b\u6d88\u5316\u5668\u5185\u79d1\u533b\u30fb\u5185\u8996\u93e1\u533b\u306e\u5f79\u5272. \u7b2c26\u56dePEG\u30fb\u5728\u5b85\u533b\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a.2022.9\uff08\u91d1\u6ca2\uff09<\/li>\n\n\n\n<li>\u6c60\u4e0a\u6b63\u3001\u5bae\ufa11\u7167\u96c4\u3001\u7551\u4e2d\u5065\u3001\u7530\u539f\u5229\u884c\u3001\u8352\u6728\u771e\u88d5\u3001\u67ff\u5d0e\u6681\u3001\u68ee\u672c\u76f4\u6a39.\u3000DAA\u6cbb\u7642\u666e\u53ca\u5f8c\u306eHCV\u60a3\u8005\u80cc\u666f\u306e\u5909\u5316\u301c\u5317\u95a2\u6771\u3067Elimination\u306f\u9032\u3093\u3067\u3044\u308b\u306e\u304b\uff1f\u3000\u7b2c26\u56de\u65e5\u672c\u809d\u81d3\u5b66\u4f1a\u5927\u4f1a. 2022.10(\u798f\u5ca1)<\/li>\n\n\n\n<li>\u65e5\u5409\u96c5\u4e5f\u3001\u65b0\u5be6\u512a\u5353\u3001\u7389\u7530\u5d07\u548c\u3001\u4e94\u982d\u4e09\u79c0\u3001\u77f3\u7530\u4fca\u6a39\u3001\u77e2\u53e3\u671b\u3001\u6c5f\u6751\u6b63\u535a\u3001\u9577\u6cbc\u82f1\u4fca\u3001\u4f0a\u8cc0\u4e0a\u7fd4\u592a\u3001\u798f\u7530\u958b\u4eba\u3001\u5965\u91ce\u8cb4\u4e4b\u3001\u661f\u5ddd\u771f\u6709\u7f8e\u3001\u6839\u672c\u5353\u3001 \u5ddd\u5d0e\u666e\u53f8\u3001\u4eac\u7530\u6709\u4ecb. \u5316\u5b66\u7642\u6cd5\u30fb\u5316\u5b66\u653e\u5c04\u7dda\u7642\u6cd5\u5f8c\u306b\u5207\u9664\u3057\u305f\u9aa8\u76e4\u5185\u81bf\u760d\u3092\u4f34\u3044\u5e83\u7bc4\u56f2\u81c0\u90e8\u76ae\u819a\u9032\u5c55\u3057\u305f\u75d4\u763b\u764c\u306e1\u4f8b. \u7b2c77\u56de\u65e5\u672c\u5927\u8178\u809b\u9580\u75c5\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012022.10(\u5343\u8449)<\/li>\n\n\n\n<li>\u5927\u95a2\u745e\u6cbb\u3001\u771f\u4e0b\u7fd4\u592a\u3001\u702c\u5c71\u4f91\u4eae\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u85e4\u679d\u771f\u53f8\u3001\u4e94\u982d\u4e09\u79c0\u3001\u8352\u6728\u771e\u88d5\u3001\u5929\u8c9d\u8ce2\u4e8c. \u6025\u6027\u81b5\u708e\u306e\u6804\u990a\u958b\u59cb\u6642\u671f\u306e\u691c\u8a0e. \u7b2c64\u56de\u65e5\u672c\u6d88\u5316\u5668\u75c5\u5b66\u4f1a\u5927\u4f1a. 2022.10(\u798f\u5ca1)<\/li>\n\n\n\n<li>\u5c71\u5ca1\u6b63\u6cbb\u3001\u79cb\u6839\u5927\u3001\u77f3\u4e95\u88d5\u7f8e\u5b50\u3001\u5ca1\u7530\u8cb4\u88d5\u3001\u6e05\u5d8b\u8b77\u4e4b\uff0eCOVID-19\u30d1\u30b9\u306e\u4f5c\u6210\u3068\u904b\u7528\u3001\u7b2c22\u56de\u65e5\u672c\u30af\u30ea\u30cb\u30ab\u30eb\u30d1\u30b9\u5b66\u4f1a\uff0c2022.11(\u5c90\u961c)<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u8b1b\u6f14\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u5929\u8c9d\u8ce2\u4e8c. \u4e2d\u5b66\u751f\u304b\u3089\u8003\u3048\u308b\u304c\u3093\u4e88\u9632. \u7b20\u9593\u5e02\u7acb\u53cb\u90e8\u4e2d\u5b66\u6821\u304c\u3093\u4e88\u9632\u6559\u80b2\u8b1b\u6f14\u4f1a\u30012022.7(\u7b20\u9593)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. \u5f53\u9662\u306e\u30ab\u30dc\u30b6\u30f3\u30c1\u30cb\u30d6\u6cbb\u7642.\u3000\u5b9f\u81e8\u5e8a\u306b\u304a\u3051\u308b\u30ab\u30dc\u30e1\u30c6\u30a3\u30af\u30b9\u3092\u7d10\u89e3\u304f\u4f1a\u30012022.9 (\u3064\u304f\u3070)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. LEN-TACE\u7642\u6cd5\u306e\u4f7f\u7528\u7d4c\u9a13. LEN-TACE Academy in \u8328\u57ce\u30012022.9 (\u3064\u304f\u3070)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. B\u578b\u809d\u708e\u518d\u6d3b\u6027\u5316\u4e88\u9632\u306e\u305f\u3081\u306e\u30ea\u30b9\u30af\u30de\u30cd\u30b8\u30e1\u30f3\u30c8. \u8328\u57ce\u770c\u809d\u708e\u6cbb\u7642WEB\u8b1b\u6f14\u4f1a\u30012022.11\uff08\u3064\u304f\u3070\uff09<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c. \u4e2d\u5b66\u751f\u304b\u3089\u8003\u3048\u308b\u304c\u3093\u4e88\u9632. \u6c34\u6238\u5e02\u7acb\u98ef\u5bcc\u4e2d\u5b66\u6821\u304c\u3093\u4e88\u9632\u6559\u80b2\u8b1b\u6f14\u4f1a\u30012022.11(\u6c34\u6238)<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c. \u304c\u3093\u306a\u3093\u3066\u95a2\u4fc2\u306a\u3044\uff1f\uff5e\u9ad8\u6821\u751f\u306e\u3068\u304d\u306b\u77e5\u3063\u3066\u304a\u304d\u305f\u304b\u3063\u305f\u3053\u3068\uff5e. \u8328\u57ce\u770c\u7acb\u90a3\u73c2\u6e4a\u9ad8\u7b49\u5b66\u6821\u304c\u3093\u6559\u80b2\u8b1b\u8a71\u30012021.11(\u3072\u305f\u3061\u306a\u304b)<\/li>\n\n\n\n<li>\u5c71\u5ca1\u6b63\u6cbb\uff0e\u5927\u8178\u764c\u306e\u4e88\u9632\u30fb\u691c\u8a3a\u3068\u5185\u8996\u93e1\u6cbb\uff0e\u304c\u3093\u770c\u6c11\u516c\u958b\u30bb\u30df\u30ca\u30fcin\u307f\u30682022.12(\u6c34\u6238)<\/li>\n\n\n\n<li>\u5c71\u5ca1\u6b63\u6cbb\uff0e\u5927\u8178\u764c\u306e\u4e88\u9632\u301c\u691c\u8a3a\u3068\u5185\u8996\u93e1\u6cbb\u7642\u301c\uff0e\u7b2c123\u56de\u7b20\u9593\u5e02\u533b\u5e2b\u4f1a\u80f8\u90e8\u75be\u60a3\u691c\u8a0e\u4f1a2022.12(\u7b20\u9593\uff0cWeb\u958b\u50ac)<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c3\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Takahashi S, Sakamoto Y, Denda T, Takashima A, Komatsu Y, Nakamura M, Ohori H, Yamaguchi T, Kobayashi Y, Baba H, Kotake M, Amagai K, Kondo H, Shimada K, Sato A, Yuki S, Okita A, Ouchi K, Komine K, Watanabe M, Morita S, Ishioka C. Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer. Cancer Sci. 112(4):1567-1578\u30012021<\/li>\n\n\n\n<li>Ochi M, Kamoshida T, Araki M, Ikegami T. Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment.World Journal of Gastroenterology 27(32):5424-5437\u30012021<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5\u3001\u5c0f\u5cf6\u5bdb\u3001\u83c5\u91ce\u76f4\u7f8e\u3001\u67f3\u5ddd\u5fb9\uff0e\u6b6f\u79d1\u533b\u9662\u306e\u305f\u3081\u306e\u5185\u79d1\u5b66\u8b1b\u5ea7\u3000\u7b2c38\u56de\u300c\u53e3\u8154\u75be\u60a3\u3068C\u578b\u809d\u708e\u2212\u809d\u75be\u60a3\u60a3\u8005\u306b\u5bfe\u3059\u308b\u6b6f\u79d1\u6cbb\u7642\u306e\u6ce8\u610f\u70b9\u3068\u306f\u2212\u300d\u3001\u88dc\u7db4\u81e8\u5e8a 54(3);293-317\u30012021<\/li>\n\n\n\n<li>\u4f0a\u8cc0\u4e0a\u7fd4\u592a\u3001\u5965\u91ce\u8cb4\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u5b89\u57ce\u82b3\u7d00\u3001\u661f\u5ddd\u771f\u6709\u7f8e\u3001\u65e5\u5409\u96c5\u4e5f\u3001\u5ddd\u5d0e\u666e\u53f8\u3001\u4eac\u7530\u6709\u4ecb\u3001\u5c71\u672c\u9806\u53f8. \u4eba\u5de5\u809b\u9580\u9665\u6ca1\u306b\u3088\u308b\u51fa\u53e3\u90e8\u72ed\u7a84\u306b\u5bfe\u3057SEMS\u7559\u7f6e\u306b\u3066\u6539\u5584\u3092\u5f97\u305f1\u4f8b\u3001Progress of Digestive Endoscopy\u300099(1);130-131\u30012021<\/li>\n\n\n\n<li>Minashi K, Yamada T, Hosaka H, Amagai K, Shimizu Y, Kiyozaki H, Sato M, Soeda A, Endo S, Ishida H, Kamoshida T, Sakai Y, Shitara K. Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer. Jpn J Clin\u3000Oncol.\u300051(10):\u30001523-1533\u30012021<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u6709\u4e0a\u8cb4\u660e\u3001\u77f3\u795e\u6d69\u5fb3\u3001\u5927\u68ee\u5065\u3001\u5c0f\u5bfa\u6cf0\u5f18\u3001\u85ea\u5d0e\u88d5\u3001\u798f\u5cf6\u4eae\u6cbb\u3001\u4eca\u91ce\u5143\u535a\u3001\u4f0a\u85e4\u8aa0\u4e8c\u3001\u5bcc\u7530\u5bff\u5f66\u3001\u79c0\u6751\u6643\u751f\u3001\u4e0a\u4e4b\u5712\u82b3\u4e00\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u592a\u7530 \u5149\u5f66\u3001\u5cb8\u5065\u592a\u90ce\u3001\u5317\u5c71 \u4e08\u4e8c. \u80c3\u764c\u8179\u819c\u64ad\u7a2e\u306b\u5bfe\u3059\u308b\u5168\u8eab\u30fb\u8179\u8154\u5185\u6295\u4e0e\u4f75\u7528\u5316\u5b66\u7642\u6cd5\u594f\u52b9\u5f8c\u306eConversion Surgery\u306e\u6cbb\u7642\u6210\u7e3e. \u7b2c121\u56de\u65e5\u672c\u5916\u79d1\u5b66\u4f1a\u5b9a\u671f\u5b66\u8853\u96c6\u4f1a\u30012021.4(\u5343\u8449)<\/li>\n\n\n\n<li>\u5b89\u90e8\u8a08\u96c4\u3001\u771f\u4e0b\u7fd4\u592a\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u5927\u95a2\u745e\u6cbb\u3001\u4e94\u982d \u4e09\u79c0\u3001\u8352\u6728\u771e\u88d5\u3001\u897f\u5854\u7fd4\u543e\u3001\u85e4\u6cbc\u516b\u6708\u3001\u661f\u5ddd\u771f\u6709\u7f8e\u3001\u4eac\u7530\u6709\u4ecb\u3001\u6589\u85e4\u4ec1\u662d\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u5c71\u672c\u9806\u53f8. EUS-FNA\u306b\u3088\u308a\u8853\u524d\u306b\u8a3a\u65ad\u3067\u304d\u305f\u81b5\u9000\u5f62\u6210\u764c\u306e1\u4f8b\u3001\u7b2c364\u56de\u65e5\u672c\u6d88\u5316\u5668\u75c5\u5b66\u4f1a\u95a2\u6771\u652f\u90e8\u4f8b\u4f1a\u30012021.4(WEB\u958b\u50ac)<\/li>\n\n\n\n<li>\u4f0a\u8cc0\u4e0a\u7fd4\u592a\u3001\u5965\u91ce\u8cb4\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u65e5\u5409\u96c5\u4e5f. \u4eba\u5de5\u809b\u9580\u9665\u6ca1\u306b\u4f34\u3046\u4eba\u5de5\u809b\u9580\u51fa\u53e3\u90e8\u76ae\u4e0b\u306e\u72ed\u7a84\u306b\u5bfe\u3057\u3066\u30b9\u30c6\u30f3\u30c8\u7559\u7f6e\u3092\u884c\u3063\u305f\u4e00\u4f8b\u3001\u7b2c114\u56de\u65e5\u672c\u6d88\u5316\u5668\u75c5\u5b66\u4f1a\u95a2\u6771\u652f\u90e8\u4f8b\u4f1a\u30012021.6(WEB\u958b\u50ac)<\/li>\n\n\n\n<li>\u77e2\u53e3\u671b\u3001\u658e\u85e4\u5c0f\u5f13\u3001\u72e9\u91ce\u4fca\u5e78\u3001\u65e5\u5409\u96c5\u4e5f\u3001\u4e94\u982d\u4e09\u79c0. \u75d4\u763b\u764c\u306e1\u4f8b\u3001\u65e5\u672c\u76ae\u819a\u79d1\u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a\u7b2c106\u56de\u4f8b\u4f1a\u30012021.8(WEB\u958b\u50ac)<\/li>\n\n\n\n<li>\u5c71\u5ca1\u6b63\u6cbb\u3001\u4e94\u982d\u4e09\u79c0\u3001\u5929\u8c9d\u8ce2\u4e8c. COVID-19\u798d\u3067\u306e\u5185\u8996\u93e1\u691c\u67fb\u306b\u304a\u3051\u308b\u9632\u8b77\u88c5\u7f6e\u306e\u958b\u767a\u3068\u4f7f\u7528\u7d4c\u9a13\u3001\u7b2c102\u56de\u65e5\u672c\u6d88\u5316\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u7dcf\u4f1a\uff08JDDW2021\uff09\u30012021.11(\u795e\u6238)<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u8b1b\u6f14\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u8352\u6728\u771e\u88d5. \u6162\u6027\u809d\u75be\u60a3\u3068\u4e9c\u925b. \u300c\u4f4e\u4e9c\u925b\u8840\u75c7\u300d\u30aa\u30f3\u30e9\u30a4\u30f3\u8b1b\u6f14\u4f1a\u30012021.6 (\u3064\u304f\u3070)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. B\u578b\u809d\u708e\u306e\u6838\u9178\u30a2\u30ca\u30ed\u30b0\u6cbb\u7642\u3068\u3010\u888b\u3068\u3058\u4f01\u753b\u3011B\u578b\u809d\u708e\u3000\u691c\u67fb\u306e\u51fa\u3057\u65b9. \u8328\u57ce\u770cHBV WEB\u8b1b\u6f14\u4f1a\u30012021.7 (\u3064\u304f\u3070)<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c. \u4e2d\u5b66\u751f\u304b\u3089\u8003\u3048\u308b\u304c\u3093\u4e88\u9632. \u7b20\u9593\u5e02\u7acb\u53cb\u90e8\u4e2d\u5b66\u6821\u304c\u3093\u4e88\u9632\u6559\u80b2\u8b1b\u6f14\u4f1a\u30012021.7(\u7b20\u9593)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. C\u578b\u809d\u708e\u60a3\u8005\u306e\u9662\u5916\u6398\u308a\u8d77\u3053\u3057\u3000\u301c\u5e83\u5831\u6d3b\u52d5\u306e\u53ef\u80fd\u6027\u301c. AbbVie HCV Expert Forum 2021\u30012021.10 (\u6771\u4eac)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. \u809d\u81d3\u5185\u79d1\u533b\u306e\u30ef\u30fc\u30af\u30d0\u30e9\u30f3\u30b9. \u8328\u57ce\u770c\u30ea\u30d5\u30ad\u30b7\u30de\u9320\u767a\u58f25\u5468\u5e74\u8a18\u5ff5\u8b1b\u6f14\u4f1a\u30012021.11 (Web\u958b\u50ac)<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c. \u304c\u3093\u306a\u3093\u3066\u95a2\u4fc2\u306a\u3044\uff1f\uff5e\u9ad8\u6821\u751f\u306e\u3068\u304d\u306b\u77e5\u3063\u3066\u304a\u304d\u305f\u304b\u3063\u305f\u3053\u3068\uff5e. \u8328\u57ce\u770c\u7acb\u90a3\u73c2\u6e4a\u9ad8\u7b49\u5b66\u6821\u304c\u3093\u6559\u80b2\u8b1b\u8a71\u30012021.11(\u3072\u305f\u3061\u306a\u304b)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. B\u578b\u809d\u708e\u306e\u6838\u9178\u30a2\u30ca\u30ed\u30b0\u6cbb\u7642\u3068\u300c\u518d\u6d3b\u6027\u5316GL\u300d\u304b\u3089\u898b\u305f\u691c\u67fb\u306e\u51fa\u3057\u65b9. \u8328\u57ce\u770cHBV WEB\u8b1b\u6f14\u4f1a\u30012021.12 (\u6771\u4eac\/Web\u958b\u50ac)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. \u65b0\u578b\u30b3\u30ed\u30ca\u3068\u809d\u708e\u8a3a\u7642. \u809d\u304c\u3093\u64b2\u6ec5\u3044\u3070\u3089\u304d\u306e\u4f1a \u5e02\u6c11\u516c\u958b\u8b1b\u5ea7\u30012021.12 (\u963f\u898b\u753a)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5.\u3000\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u4f7f\u7528\u5f8c\u306b\u767a\u75c7\u3057\u305firAE\u306b\u3088\u308b\u4e00\u5256\u691c\u4f8b. \u7b2c36\u56de\u770c\u5357\u30fb\u770c\u897f\u809d\u75be\u60a3\u7814\u7a76\u4f1a\u30012022.2 (\u3064\u304f\u3070)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5.\u3000\u5f53\u9662\u306b\u304a\u3051\u308bC\u578b\u809d\u708e\u8a3a\u7642\u3000\u305d\u306e\u5f8c. \u7b2c13\u56de\u809d\u75be\u60a3\u5730\u57df\u9023\u643a\u306e\u4f1a\u3001\u30002022.2 (\u6c34\u6238)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5.\u3000\u5f53\u9662\u306eTAF\u8a3a\u7642\u3068\u300c\u518d\u6d3b\u6027\u5316GL\u300d\u306b\u3088\u308bB\u578b\u809d\u708e\u691c\u67fb\u306e\u51fa\u3057\u65b9. \u8328\u57ce\u770c HBV Web Seminar\u30012022.3 (\u3064\u304f\u3070)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5.\u3000C\u578b\u809d\u708e\u6cbb\u7642\u3068\u79c1\u3000(\u304a\u307e\u3051\u3000B\u578b\u809d\u708e\u6cbb\u7642). \u30aa\u30ec\u6d41\uff01\u201d\u6d88\u5316\u5668\u9053\u5834\u201d\u3000\u7b2c\u4e8c\u8a71\u30012022.3 (Web\u958b\u50ac)<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c2\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u8352\u6728\u771e\u88d5\uff1a\u5c02\u9580\u533b\u306e\u76f4\u63a5\u4ecb\u5165\u306b\u3088\u308b C \u578b\u809d\u708e\u60a3\u8005\u306e\u9662\u5185\u62fe\u3044\u4e0a\u3052\u3001\u8328\u57ce\u770c\u7acb\u75c5\u9662\u533b\u5b66\u96d1\u8a8c37(1);17-20\u30012020<\/li>\n\n\n\n<li>Kawazoe A, Yamaguchi K, Yasui H, Negoro Y, Azuma M, Amagai K, Hara H, Baba H, Tsuda M, Hosaka H, Kawakami H, Oshima T, Omuro Y, Machida N, Esaki T, Yoshida K, Nishina T, Komatsu Y, Han SR, Shiratori S, Shitara K. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric\/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. Eur J Cancer 129:97-106, 2020<\/li>\n\n\n\n<li>Iijima K, Oozeki M, Ikeda K, Honda H, Ishibashi H, Yamaoka M, Fujieda S, Saitoh H, Goto M, Araki M, Amagai K. A case of small bowel adenocarcinoma wherein nivolumab conferred temporary benefit in disease control. Clin J Gastroenterol 13(3):372-376, 2020<\/li>\n\n\n\n<li>Kawazoe A, Ando T, Hosaka H, Fujita J, Koeda K, Nishikawa K, Amagai K, Fujitani K, Ogata K, Watanabe K, Yamamoto Y, Shitara K. Safety and activity of trifluridine\/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 rial. Lancet Gastroenterol Hepatol 6(3):209-217, 2021<\/li>\n\n\n\n<li>Fujitani K, Shitara K, Takashima A, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Kimura Y, Amagai K, Hosaka H, Komatsu Y, Shimada K, Kawabata R, Ohdan H, Kodera Y, Nakamura M, Nakajima TE, Miyata Y, Moriwaki T, Kusumoto T, Nishikawa K, Ogata K, Shimura M, Morita S, Koizumi W. Correction to: Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial. Gastric Cancer 24(2):477-478, 2021<\/li>\n\n\n\n<li>Fujitani K, Shitara K, Takashima A, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Kimura Y, Amagai K, Hosaka H, Komatsu Y, Shimada K, Kawabata R, Ohdan H, Kodera Y, Nakamura M, Nakajima TE, Miyata Y, Moriwaki T, Kusumoto T, Nishikawa K, Ogata K, Shimura M, Morita S, Koizumi W. Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial. Gastric Cancer 24(2):467-476, 2021<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u6df1\u5ddd\u525b\u751f\u3001\u77f3\u795e\u6d69\u5fb3\u3001\u5927\u68ee\u5065\u3001\u5c0f\u5bfa\u6cf0\u5f18\u3001\u85ea\u5d0e\u88d5\u3001\u798f\u5cf6\u4eae\u6cbb\u3001\u4eca\u91ce\u5143\u535a\u3001\u4e09\u6fa4\u4e00\u6210\u3001\u5bcc\u7530\u5bff\u5f66\u3001\u79c0\u6751\u6643\u751f\u3001\u6709\u4e0a\u8cb4\u660e\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u8fbb\u9756\u3001\u6960\u672c\u54f2\u4e5f\u3001\u5cb8\u5065\u592a\u90ce\u3001\u4e0a\u7530\u4fee\u543e\u3001\u4f0f\u7530\u5e78\u592b\u3001\u4eca\u6751\u548c\u5f18\u3001\u7dd2\u65b9\u674f\u4e00\u3001\u5317\u5c71\u4e08\u4e8c. \u521d\u8a3a\u6642\u5207\u9664\u4e0d\u80fd\u80c3\u764c\u306b\u5bfe\u3059\u308b conversion surgery \u306e\u610f\u7fa9\u3010International\u3011\u8179\u819c\u64ad\u7a2e\u3092\u4f34\u3046\u9032\u884c\u80c3\u764c\u75c7\u4f8b\u306b\u5bfe\u3059\u308b\u8179\u8154\u5185\u6295\u4e0e\u3092\u4f34\u3046\u5168\u8eab\u5316\u5b66\u7642\u6cd5\u5f8c\u306e\u5916\u79d1\u624b\u8853\u306e\u6210\u7e3e(Surgical outcomes for advanced gastric cancer with peritoneal metastases after intraperitoneal and systemic chemotherapy). \u7b2c 120 \u56de\u65e5\u672c\u5916\u79d1\u5b66\u4f1a\u5b9a\u671f\u5b66\u8853\u96c6\u4f1a\u30012020.8\uff08\u6a2a\u6d5c\uff09<\/li>\n\n\n\n<li>Kamoshida T, Ochi M, Ikegami T, Araki M, Yamaguchi Y, Hamano Y, Ohkawara H, Ohkawara A, Kakinoki N, Hirai S, Yanaka A. Hand-foot skin reaction as a prognostic marker in patients with hepatocellular carcinoma treated with sorafenib influences adherence and prognosis depending on the intervention method: A multi-institutional study. ESMO Virtual Congress 2020\u30012020.9<\/li>\n\n\n\n<li>\u5c0f\u6797\u5927\u4ecb\u3001\u77f3\u795e\u6d69\u5fb3\u3001\u5927\u68ee\u5065\u3001\u5c0f\u5bfa\u6cf0\u5f18\u3001\u85ea\u5d0e\u88d5\u3001\u798f\u5cf6\u4eae\u6cbb\u3001\u4eca\u91ce\u5143\u535a\u3001\u4f0a\u85e4 \u8aa0\u4e8c\u3001\u5bcc\u7530\u5bff\u5f66\u3001\u79c0\u6751\u6643\u751f\u3001\u6709\u4e0a\u8cb4\u660e\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u592a\u7530\u5149\u5f66\u3001\u5cb8\u5065\u592a\u90ce\u3001\u5317\u5c71 \u4e08\u4e8c. \u6d88\u5316\u7ba1\u764c\u306e\u6cbb\u7642\u6226\u7565\u8179\u819c\u64ad\u7a2e\u3092\u4f34\u3046\u80c3\u764c\u306b\u5bfe\u3059\u308b\u8179\u8154\u5185\u5316\u5b66\u7642\u6cd5\u304a\u3088\u3073\u5168\u8eab\u5316\u5b66\u7642\u6cd5\u594f\u529f\u5f8c\u306e\u80c3\u5207\u9664\u8853. 58 \u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012020.10\uff08\u4eac\u90fd\uff09<\/li>\n\n\n\n<li>\u5c71\u5ca1\u6b63\u6cbb\u3001\u4e94\u982d\u4e09\u79c0\u3001\u5927\u95a2\u745e\u6cbb\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u83c5\u8c37\u660e\u5fb3\u3001\u8352\u6728\u771e\u88d5\u3001\u5929\u8c9d\u8ce2\u4e8c, \u76f4\u8178\u795e\u7d4c\u5185\u5206\u6ccc\u816b\u760d 25 \u4f8b\u306e\u6cbb\u7642\u6210\u7e3e\u3068\u9577\u671f\u7d4c\u904e. \u7b2c 100 \u56de\u65e5\u672c\u6d88\u5316\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u7dcf\u4f1a\u30012020.11\uff08\u795e\u6238\uff09<\/li>\n\n\n\n<li>\u83c5\u8c37\u660e\u5fb3\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u8352\u6728\u771e\u88d5\u3001\u5927\u95a2\u745e\u6cbb\u3001\u77f3\u6a4b\u8087\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u4e94\u982d\u4e09\u79c0. \u5f53\u9662\u306b\u304a\u3051\u308b\u5207\u9664\u4e0d\u80fd\u9032\u884c\u30fb\u518d\u767a\u5927\u8178\u764c\u3067\u306e TAS-102 \u306e\u4f7f\u7528\u7d4c\u9a13. \u7b2c 62 \u56de\u65e5\u672c\u6d88\u5316\u5668\u75c5\u5b66\u4f1a\u5927\u4f1a\u30012020.11\uff08\u795e\u6238)<\/li>\n\n\n\n<li>\u68ee\u8107\u4fca\u548c\u3001\u5cf6\u7530\u5149\u751f\u3001\u9152\u4e95\u7fa9\u6cd5\u3001\u77f3\u7530\u535a\u4fdd\u3001\u9060\u85e4\u614e\u6cbb\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u5009\u6301\u82f1\u548c\u3001 \u6839\u6765\u88d5\u4e8c\u3001\u4ec1\u79d1\u667a\u88d5\u3001\u5175\u982d\u4e00\u4e4b\u4ecb. \u9ad8\u9f62\u8005\u6d88\u5316\u7ba1\u764c\u8a3a\u7642\u306b\u304a\u3051\u308b\u5316\u5b66\u7642\u6cd5\u30fb\u5916\u79d1\u624b\u8853\u306e\u9069\u5fdc\u3068\u5de5\u592b \u9ad8\u9f62\u5927\u8178\u764c\u60a3\u8005\u306b\u304a\u3051\u308b\u30d5\u30c3\u5316\u30d4\u30ea\u30df\u30b8\u30f3\u7cfb\u85ac\u5264+\u30d9\u30d0\u30b7\u30ba\u30de\u30d6\u306e\u52b9\u679c\u5b89\u5168\u6027\u306b\u5bfe\u3059\u308b\u5e74\u9f62\u306e\u5f71\u97ffJ-BLUE \u3068 J-SAVER \u8a66\u9a13\u306e\u7d71\u5408\u89e3\u6790. \u7b2c 17 \u56de\u65e5\u672c\u6d88\u5316\u7ba1\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012021.2\uff08\u5927\u962a\uff09<\/li>\n\n\n\n<li>\u4fdd\u5742\u5c1a\u5fd7\u3001\u5ddd\u6dfb\u5f6c\u4eba\u3001\u5b89\u85e4\u5b5d\u5c06\u3001\u85e4\u7530\u6df3\u4e5f\u3001\u80a5\u7530\u572d\u4ecb\u3001\u897f\u5ddd\u548c\u5b8f\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001 \u85e4\u8c37\u548c\u6b63\u3001\u8a2d\u697d\u7d18\u5e73. \u9032\u5c55\u80c3\u764c\u306b\u5bfe\u3059\u308b\u85ac\u7269\u6cbb\u7642\u306f\u3053\u308c\u304b\u3089\u3069\u3046\u5909\u308f\u308b\u304b? \u5207\u9664\u4e0d\u80fd\u9032\u884c\u518d\u767a\u80c3\u764c\u306b\u5bfe\u3059\u308b trifluridine\/tipiracil+ramucirumab \u306e\u7b2c II \u76f8\u8a66\u9a13(A phase II study of trifluridine\/tipiracil and<br>ramucirumab in patients with advanced gastric cancer). \u7b2c 93 \u56de\u65e5\u672c\u80c3\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012021.3\uff08\u5927\u962a\uff09<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u8b1b\u6f14\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u8352\u6728\u771e\u88d5. \u5f53\u9662\u306b\u304a\u3051\u308b C \u578b\u809d\u708e\u8a3a\u7642 \uff5eDAA \u6cbb\u7642\u306e\u73fe\u6cc1\u3068\u9662\u5185\u62fe\u3044\u4e0a\u3052\uff5eG-STATION Plus WEB \u8b1b\u6f14\u4f1a\u30012020.11(\u3064\u304f\u3070)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. \u809d\u81d3\u304c\u3093\u306b\u3064\u3044\u3066 \u7b2c 3 \u56de\u809d\u708e\u533b\u7642\u30b3\u30fc\u30c7\u30a3\u30cd\u30fc\u30bf\u30fcWEB \u30bb\u30df\u30ca\u30fc\u30012020.11(\u3064\u304f\u3070)<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c. \u304c\u3093\u306a\u3093\u3066\u95a2\u4fc2\u306a\u3044\uff1f\uff5e\u9ad8\u6821\u751f\u306e\u3068\u304d\u306b\u77e5\u3063\u3066\u304a\u304d\u305f\u304b\u3063\u305f\u3053\u3068\uff5e\u8328\u57ce\u770c\u7acb\u90a3\u73c2\u6e4a\u9ad8\u7b49\u5b66\u6821\u304c\u3093\u6559\u80b2\u8b1b\u8a71\u30012020.11(\u3072\u305f\u3061\u306a\u304b)<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c. \u4e2d\u5b66\u751f\u304b\u3089\u8003\u3048\u308b\u304c\u3093\u4e88\u9632 \u7b20\u9593\u5e02\u7acb\u53cb\u90e8\u4e2d\u5b66\u6821\u304c\u3093\u4e88\u9632\u6559\u80b2\u8b1b\u6f14\u4f1a\u30012020.12(\u7b20\u9593)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. C \u578b\u809d\u708e\u306e\u9662\u5185\u62fe\u3044\u4e0a\u3052\u3068\u9662\u5916\u6398\u308a\u8d77\u3053\u3057m3.com \u8b1b\u6f14\u4f1a\u30012021.3(\u3064\u304f\u3070)<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u305d\u306e\u4ed6\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u8352\u6728\u771e\u88d5. C \u578b\u809d\u708e\u60a3\u8005\u62fe\u3044\u4e0a\u3052\u6298\u8fbc\u30c1\u30e9\u30b7\uff08\u914d\u5e03\uff09\u30a2\u30c3\u30f4\u30a3\u5408\u540c\u4f1a\u793e\u30012020.11\uff08\u7b20\u9593\u30fb\u5c0f\u7f8e\u7389\uff09<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c\u5143\u5e74<\/h3>\n\n\n\n<p>\u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u4f0a\u6771 \u5b8c\u3001\u8352\u6728\u771e\u88d5\uff1a\u5316\u81bf\u6027\u809d\u81bf\u760d\u306b\u8179\u75db\u3092\u4f34\u3046\u6761\u4ef6(Factors affecting the occurrence of abdominal pain in patients with pyogenic liver abscess)\uff0e\u8328\u57ce\u770c\u7acb\u75c5\u9662\u533b\u5b66\u96d1\u8a8c 36(1)\uff1b11-18,2019<\/li>\n\n\n\n<li>Minashi K, Amagai K, Muto M. Efficacy of Endoscopic Resection and Selective Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology, 157(2):382-390, 2019<\/li>\n\n\n\n<li>Moriwaki T, Amagai K, Hyodo I. Phase II study of S-1 on alternate days plus bevacizumab in patients aged \u2265 75 years with metastatic colorectal cancer (J-SAVER). Int J Clin Oncol, 24(10):1214-1222, 2019<\/li>\n\n\n\n<li>Takahari D, Amagai K, Yamaguchi K. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naive, HER2-positive advanced gastric cancer. Gastric Cancer, 22(6):1238-1246, 2019 Yamada Y, Amagai K, Hyodo I. Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer. Cancer Sci, 110(9):2875-2883, 2019<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u4f0a\u6771 \u5b8c\u3001\u8352\u6728\u771e\u88d5\uff0e\u5316\u81bf\u6027\u809d\u81bf\u760d\u306b\u8179\u75db\u3092\u4f34\u3046\u6761\u4ef6\uff0e\u533b\u5b66\u751f\u30fb\u7814\u4fee\u533b\u306e\u65e5\u672c\u5185\u79d1\u5b66\u4f1a\u3053\u3068\u306f\u3058\u3081 2019 \u540d\u53e4\u5c4b\u30012019.4(\u540d\u53e4\u5c4b)<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c\u3001\u4e0a\u4e95\u96c5\u54c9\uff0e\u5c0f\u5150\u751f\u6d3b\u7fd2\u6163\u75c5\u691c\u8a3a\u306b\u4f75\u305b\u3066\u958b\u59cb\u3055\u308c\u305f\u4e2d\u5b66\u751f\u5bfe\u8c61\u306e\u30d4\u30ed\u30ea\u83cc\u691c\u8a3a\uff0e\u7b2c25 \u56de \u65e5\u672c\u30d8\u30ea\u30b3\u30d0\u30af\u30bf\u30fc\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012019.5\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n\n\n\n<li>\u4e2d\u6751\u660c\u592a\u90ce\u3001\u52a0\u85e4\u5143\u55e3\u3001\u5929\u8c9d\u8ce2\u4e8c\uff0e\u9664\u83cc\u5f8c\u9577\u671f\u89b3\u5bdf\u4f8b H.pylori \u9670\u6027\/\u9664\u83cc\u62b5\u6297\u6027 MALT \u30ea\u30f3\u30d1\u816b\u306b \u5bfe\u3059\u308b\u9ad8\u7528\u91cf\u30af\u30e9\u30ea\u30b9\u30ed\u30de\u30a4\u30b7\u30f3\u5358\u5264\u7642\u6cd5 \u672c\u90a6\u591a\u65bd\u8a2d\u5171\u540c\u8a66\u9a13\uff0e\u7b2c 25 \u56de\u65e5\u672c\u30d8\u30ea\u30b3\u30d0\u30af\u30bf\u30fc\u5b66\u4f1a \u5b66\u8853\u96c6\u4f1a\u30012019.5\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n\n\n\n<li>\u6c60\u7530\u516c\u53f2\u3001\u85e4\u679d\u771f\u53f8\u3001\u5965\u5742\u62d3\u5fd7\uff0e\u81b5\u304c\u3093\u60a3\u8005\u306e\u30b5\u30dd\u30fc\u30c6\u30a3\u30d6\u30b1\u30a2 \u81b5\u304c\u3093\u6559\u5ba4\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7\u306e\u6d3b\u52d5 \u5831\u544a \u7b2c 8 \u56de\u67cf\u306e\u8449\u958b\u50ac\u3092\u7d42\u3048\u3066\uff0e\u7b2c 50 \u4f1a\u65e5\u672c\u81b5\u81d3\u5b66\u4f1a\u5927\u4f1a\u30012019.7\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>\u4e94\u8012\u4f73\u592e\u91cc\u3001\u8352\u6728\u771e\u88d5\u3001\u9234\u6728\u7f8e\u52a0\uff0e \u514d\u75ab\u6291\u5236\u30fb\u5316\u5b66\u7642\u6cd5\u60a3\u8005\u306b\u304a\u3051\u308b B \u578b\u809d\u708e\u30a6\u30a4\u30eb\u30b9\u30b9\u30af\u30ea\u30fc \u30cb\u30f3\u30b0\u5b9f\u65bd\u72b6\u6cc1\u8abf\u67fb\uff0e\u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u95a2\u6771\u30d6\u30ed\u30c3\u30af\u7b2c 49 \u56de\u5b66\u8853\u5927\u4f1a\u30012019.8\uff08\u7532\u5e9c\uff09<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. \u5f53\u9662\u306e\u80c6\u9053\u764c\u5316\u5b66\u7642\u6cd5\uff0e\u7b2c 55 \u56de\u65e5\u672c\u80c6\u9053\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012019.10\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n\n\n\n<li>\u5f8c\u85e4 \u52b1\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u68ee\u7530\u667a\u8996\uff0eTRICOLORE \u8a66\u9a13\u306b\u57fa\u3065\u3044\u305f\u8ee2\u79fb\u3092\u6709\u3059\u308b\u5927\u8178\u764c\u306b\u5bfe\u3059\u308b\u4e00\u6b21\u6cbb\u7642 \u306e\u8cbb\u7528\u52b9\u679c\u5206\u6790\uff0e\u7b2c 57 \u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012019.10\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n<li>\u4f50 \u85e4 \u6e29 \u3001 \u5929 \u8c9d \u8ce2 \u4e8c \u3001 \u77f3 \u5ca1 \u5343 \u52a0 \u53f2 \uff0e TRICOLORE \u8a66 \u9a13 ( \u5927\u8178\u764c\u7b2c 3 \u76f8 \u8a66\u9a13:mFOLFOX6\/CapeOX+Bev vs S-1\/CPT-11+Bev)\u306e QOL \u89e3\u6790\uff0e\u7b2c 57 \u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012019.10\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n<li>\u77f3\u795e\u6d69\u5fb3\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u5317\u5c71\u4e08\u4e8c\uff0e\u80c3\u764c Up to Date \u8179\u819c\u64ad\u7a2e\u967d\u6027\u80c3\u764c\u306b\u5bfe\u3059\u308b\u8179\u8154\u5185\u5316\u5b66\u7642\u6cd5\u8179 \u8154\u5185\u5316\u5b66\u7642\u6cd5\u7814\u7a76\u4f1a\u306e\u81e8\u5e8a\u8a66\u9a13\uff0e\u7b2c 57 \u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012019.10\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n<li>\u85e4\u8c37\u548c\u6b63\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u571f\u4e95\u4fca\u5f66\uff0e\u65b0\u898f\u81e8\u5e8a\u8a66\u9a13\u6700\u65b0\u60c5\u5831 \u9032\u884c\u518d\u767a\u80c3\u764c\u306b\u5bfe\u3059\u308b FTD\/TPI(TAS102) \u306e\u56fd\u969b\u5171\u540c\u8a66\u9a13(TAGS)\u3067\u306e\u65e5\u672c\u4eba\u96c6\u56e3\u306e\u691c\u8a0e\uff0e\u7b2c 57 \u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012019.10\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n<li>\u5c71\u5ca1\u6b63\u6cbb\u3001\u4e94\u982d\u4e09\u79c0\u3001\u5927\u95a2\u745e\u6cbb\u3001\u98ef\u5cf6\u4e00\u98db\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b \u8087\u3001\u85e4\u679d\u771f\u53f8\u3001\u8352\u6728\u771e\u88d5\u3001\u5929\u8c9d\u8ce2\u4e8c\uff0e\u30dd\u30ea\u30fc\u30d7\u69d8\u5f62\u614b\u3092\u5448\u3057\u305f\u80c3\u578b\u816b\u760d 6 \u4f8b\u306e\u691c\u8a0e\uff0e\u7b2c 27 \u56de\u65e5\u672c\u6d88\u5316\u5668\u95a2\u9023\u5b66\u4f1a\u9031\u9593 \u30012019.11\uff08\u795e\u6238\uff09<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5\uff0e\u96fb\u5b50\u30ab\u30eb\u30c6\u30a2\u30e9\u30fc\u30c8\u30b7\u30b9\u30c6\u30e0\u306b\u983c\u3089\u306a\u3044 C \u578b\u809d\u708e\u60a3\u8005\u306e\u9662\u5185\u3072\u308d\u3044\u4e0a\u3052\uff0e\u7b2c 23 \u56de\u65e5\u672c \u809d\u81d3\u5b66\u4f1a\u5927\u4f1a\u30012019.11\uff08\u795e\u6238\uff09<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u8b1b\u6f14\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u4e94\u982d\u4e09\u79c0\uff0e\u6d88\u5316\u5668\u7cfb\u306e\u6307\u5b9a\u96e3\u75c5\u306b\u3064\u3044\u3066\uff5e\u6709\u75c5\u7387\u306e\u9ad8\u3044\u75be\u60a3\u3092\u4e2d\u5fc3\u306b\uff5e\uff0eH31 \u5e74\u5ea6\u96e3\u75c5\u6307\u5b9a\u533b\u5354\u529b \u96e3\u75c5\u6307\u5b9a\u533b\u7814\u4fee\u4f1a\u30012020.6\uff08\u3064\u304f\u3070\uff09<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5\uff0eC \u578b\u809d\u708e\u3068\u5e73\u6210\u306e 30 \u5e74\uff0e\u6c34\u6238\u6d88\u5316\u5668\u30d5\u30a9\u30fc\u30e9\u30e0\u30012019.7\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5\uff0e\u8102\u80aa\u809d\u3068\u809d\u81d3\u304c\u3093. \u7b2c 106 \u56de\u65e5\u672c\u6d88\u5316\u5668\u75c5\u5b66\u4f1a\u95a2\u6771\u652f\u90e8\u5e02\u6c11\u516c\u958b\u8b1b\u5ea7\u30012019.7\uff08\u571f\u6d66\uff09<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c\uff0e\u4e2d\u5b66\u751f\u304b\u3089\u8003\u3048\u308b\u304c\u3093\u4e88\u9632\uff0e\u7b20\u9593\u5e02\u7acb\u53cb\u90e8\u4e2d\u5b66\u6821\u304c\u3093\u4e88\u9632\u6559\u80b2\u8b1b\u6f14\u4f1a\u30012019.7\uff08\u7b20\u9593\uff09<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5\uff0e\u304c\u3093\u5316\u5b66\u7642\u6cd5\u306b\u304a\u3051\u308b B \u578b\u809d\u708e\u306e\u518d\u6d3b\u6027\u5316\uff0e\u5730\u57df\u304c\u3093\u8a3a\u7642\u9023\u643a\u62e0\u70b9\u75c5\u9662\u85ac\u5264\u90e8\u30bb\u30df\u30ca\u30fc\u3001 2019.8\uff08\u3064\u304f\u3070\uff09<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c\uff0e\u5927\u8178\u304c\u3093\u5316\u5b66\u7642\u6cd5\u306e\u73fe\u72b6\u3068\u5c55\u671b. \u53e4\u6cb3\u5730\u533a\u764c\u30d5\u30a9\u30fc\u30e9\u30e0\u30012019.9(\u53e4\u6cb3)<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c\uff0e\u304c\u3093\u306a\u3093\u3066\u95a2\u4fc2\u306a\u3044\uff1f\uff5e\u9ad8\u6821\u751f\u306e\u3068\u304d\u306b\u77e5\u3063\u3066\u304a\u304d\u305f\u304b\u3063\u305f\u3053\u3068\uff5e. \u8328\u57ce\u770c\u7acb\u90a3\u73c2\u6e4a\u9ad8\u7b49 \u5b66\u6821\u304c\u3093\u6559\u80b2\u8b1b\u8a71\u30012019.11(\u3072\u305f\u3061\u306a\u304b)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5\uff0e\u809d\u81d3\u75c5 2020\uff5eB \u578b\u30fbC \u578b\u30fb\u8102\u80aa\u809d\uff5e. \u7b2c 25 \u56de\u81e8\u5e8a\u691c\u67fb\u30d5\u30a9\u30fc\u30e9\u30e0\u30012020.2\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5\uff0e\u5f53\u9662\u306b\u304a\u3051\u308b C \u578b\u809d\u708e\u8a3a\u7642\uff0e\u7b2c 11 \u56de\u809d\u75be\u60a3\u5730\u57df\u9023\u643a\u306e\u4f1a\u30012020.2\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c\uff0e\u80c3\u764c\u306e\u6cbb\u7642\u306b\u3064\u3044\u3066\uff0e\u304c\u3093\u85ac\u7269\u7642\u6cd5\u8a8d\u5b9a\u85ac\u5264\u5e2b\u7814\u4fee\u30012020.2(\u7b20\u9593)<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u5e73\u621030\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Kato S, Imai H, Gamoh M, Takahata T, Ohori H, Yasuda K, Niitani T, Murakawa Y, Amagai K, Isobe H, Shindo Y, Kuroki M, Sakamoto Y, Shimodaira H, Yoshioka T, Ishioka C.. Intermittent withdrawal of oxaliplatin for alleviating neurotoxicity during oxaliplatin-based chemotherapy for Japanese patients with inoperable or metastatic colorectal cancer: A phase 2 multicenter study. Tohoku J Exp Med, 245(1):21-28, 2018<\/li>\n\n\n\n<li>Mabe K, Okuda M, Kikuchi S, Amagai K, Yoshimura R, Kato M, Sakamoto N, Asaka M. Randomized controlled trial: PPI-based triple therapy containing metronidazole versus clarithromycin as first-line treatment for Helicobacter pylori in adolescents and young adults in Japan. J Infect Chemother, 24(7):538-543, 2018.<\/li>\n\n\n\n<li>Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K, Kadowaki S, Miwa H, Yamaguchi H, Yamaguchi T, Miyaji T, Kitayama J. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol, 36(19):1922-1929, 2018<\/li>\n\n\n\n<li>Takashima A, Shitara K, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Kimura Y, Amagai K, Fujii H, Muro K, Esaki T, Choda Y, Takano T, Chin K, Sato A, Goto M, Fukushima N, Hara T, Machida N, Ohta M, Boku N, Shimura M, Morita S, Koizumi W. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial. Gastric Cancer, 22(1):155-163, 2019<\/li>\n\n\n\n<li>Nishina T, Azuma M, Nishikawa K, Gotoh M, Bando H, Sugimoto N, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Mitome T, Kageyama H, Hyodo I. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin. Gastric Cancer, 22(1):138-146, 2019<\/li>\n\n\n\n<li>Hamaguchi T, Tsuji A, Yamaguchi K, Takeda K, Uetake H, Esaki T, Amagai K, Sakai D, Baba H, Kimura M, Matsumura Y, Tsukamoto T. A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients. Cancer Chemother Pharmacol, 82(6):1021-1029, 2018<\/li>\n\n\n\n<li>\u77f3\u6a4b\u8087\uff0c\u4e94\u982d\u4e09\u79c0\uff0c\u85e4\u679d\u771f\u53f8\uff0c\u5c71\u5ca1\u6b63\u6cbb\uff0c\u672c\u591a\u5bdb\u4e4b\uff0c\u5927\u95a2\u745e\u6cbb\uff0c\u5929\u8c9d\u8ce2\u4e8c\uff0c\u98ef\u5cf6\u4e00\u98db\uff1a\u7a7f\u5b54\u4f8b\u304b\u3089\u5927\u8178\u30b9\u30c6\u30f3\u30c8\u306e\u5b89\u5168\u306a\u7559\u7f6e\u6cd5\u3084\u9069\u5fdc\u3092\u63a2\u308b. Progress of Digestive Endoscopy93(1);35-40, 2018<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u4f0a\u6771\u5b8c\u3001\u8352\u6728\u771e\u88d5\u3001\u93d1\u6728\u5b5d\u4e4b. Klebsiella pneumoniae \u306b\u3088\u308b\u809d\u81bf\u760d: \u4ed6\u8d77\u56e0\u83cc\u306b\u3088\u308b\u809d\u81bf\u760d\u3068\u306e\u9055\u3044. \u533b\u5b66\u751f\u30fb\u7814\u4fee\u533b\u306e\u65e5\u672c\u5185\u79d1\u5b66\u4f1a\u3053\u3068\u306f\u3058\u3081 2018 \u4eac\u90fd\u30012018.4(\u4eac\u90fd)<\/li>\n\n\n\n<li>\u77f3\u6a4b\u8087\u3001\u677e\u5d0e\u88d5\u5e78\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u85e4\u679d\u771f\u53f8\u3001\u5c0f\u677e\u7fa9\u5e0c\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u702c\u5c71\u4f91\u4eae\u3001\u8352\u6728\u771e\u88d5\u3001\u4e94\u982d\u4e09\u79c0\u3001\u5927\u95a2\u745e\u6cbb\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u98ef\u5cf6\u4e00\u98db. \u7a7f\u5b54 2 \u4f8b\u3092\u542b\u3081\u305f\u5927\u8178\u30b9\u30c6\u30f3\u30c8\u7d4c\u9a13\u304b\u3089\u3001\u3088\u308a\u5b89\u5168\u306a\u7559\u7f6e\u6cd5\u3084\u9069\u5fdc\u3092\u63a2\u308b.\u7b2c 106 \u56de\u65e5\u672c\u6d88\u5316\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u95a2\u6771\u652f\u90e8\u4f8b\u4f1a\uff642018.6(\u6771\u4eac)<\/li>\n\n\n\n<li>\u4e2d\u6751\u660c\u592a\u90ce\u3001\u52a0\u85e4\u5143\u55e3\uff64\u5929\u8c9d\u8ce2\u4e8c. \u9664\u83cc\u5f8c\u9577\u671f\u7d4c\u904e\u306e\u554f\u984c\u70b9 H.pylori \u9670\u6027\/\u9664\u83cc\u62b5\u6297\u6027\u6d88\u5316\u7ba1MALT \u30ea\u30f3\u30d1\u816b\u306b\u5bfe\u3059\u308b\u9ad8\u7528\u91cf\u30af\u30e9\u30ea\u30b9\u30ed\u30de\u30a4\u30b7\u30f3\u5358\u5264\u7642\u6cd5(\u7b2c\u4e00\u5831). \u7b2c 24 \u56de\u65e5\u672c\u30d8\u30ea\u30b3\u30d0\u30af\u30bf\u30fc\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012018.6(\u5927\u5206)<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c\u3001\u85e4\u679d\u771f\u53f8. \u75c5\u9662\u8077\u54e1\u306e\u5b9a\u671f\u5065\u5eb7\u8a3a\u65ad\u3092\u6d3b\u7528\u3057\u305f ABC \u691c\u8a3a(5 \u5e74\u524d\u3068\u306e\u6bd4\u8f03). \u7b2c 24\u56de \u65e5\u672c\u30d8\u30ea\u30b3\u30d0\u30af\u30bf\u30fc\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012018.6(\u5927\u5206)<\/li>\n\n\n\n<li>\u4f0a\u6771\u5b8c\uff64\u8352\u6728\u771e\u88d5. Klebsiella pneumoniae \u306b\u3088\u308b\u809d\u81bf\u760d\u3068\u4ed6\u8d77\u56e0\u83cc\u306b\u3088\u308b\u809d\u81bf\u760d\u306e\u9055\u3044: \u975e\u78ba\u8a3a\u4f8b\u3092\u542b\u3081\u305f\u691c\u8a0e. \u7b2c 17 \u56de\u65e5\u672c\u75c5\u9662\u7d9c\u5408\u8a3a\u7642\u533b\u5b66\u4f1a\u7dcf\u4f1a\u30012018.9(\u5c90\u961c)<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c. \u8077\u54e1\u306e\u5b9a\u671f\u5065\u5eb7\u8a3a\u65ad\u3092\u6d3b\u7528\u3057\u305f ABC \u691c\u8a3a\u3068\u55ab\u7159\u72b6\u6cc1\u8abf\u67fb 5 \u5e74\u524d\u3068\u306e\u6bd4\u8f03. \u7b2c 77\u56de \u65e5\u672c\u516c\u8846\u885b\u751f\u5b66\u4f1a\u7dcf\u4f1a\u30012018.10(\u90e1\u5c71)<\/li>\n\n\n\n<li>\u85e4\u679d\u771f\u53f8(\u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u8328\u57ce\u770c\u5730\u57df\u304c\u3093\u30bb\u30f3\u30bf\u30fc \u6d88\u5316\u5668\u5185\u79d1), \u5929\u8c9d\u8ce2\u4e8c\u3001\u8352\u6728\u771e\u88d5\u3001\u4e94\u982d\u4e09\u79c0\u3001\u5927\u95a2\u745e\u6cbb\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u77f3\u6a4b\u8087\u3001\u702c\u5c71\u4f91\u4eae\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u98ef\u5cf6\u4e00\u98db. \u75c5\u9662\u8077\u54e1\u306b\u304a\u3051\u308b\u80c3\u764c\u30ea\u30b9\u30af\u691c\u8a3a(ABC \u691c\u8a3a) 5 \u5e74\u524d\u3068\u306e\u6bd4\u8f03. \u7b2c 56 \u56de\u65e5\u672c\u6d88\u5316\u5668\u304c\u3093\u691c\u8a3a\u5b66\u4f1a\u5927\u4f1a\u30012018.11(\u795e\u6238)<\/li>\n\n\n\n<li>\u9060\u85e4\u614e\u6cbb\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u5175\u982d\u4e00\u4e4b\u4ecb. \u9ad8\u9f62\u8005(75 \u6b73\u4ee5\u4e0a)\u5207\u9664\u4e0d\u80fd\u30fb\u518d\u767a\u5927\u8178\u764c\u306b\u5bfe\u3059\u308b\u9694\u65e5 S-1\u6295\u4e0e+bevacizumab \u4f75\u7528\u7642\u6cd5\u306e\u591a\u65bd\u8a2d\u5171\u540c\u7b2c II \u76f8\u81e8\u5e8a\u8a66\u9a13. \u7b2c 60 \u56de\u65e5\u672c\u6d88\u5316\u5668\u75c5\u5b66\u4f1a\u5927\u4f1a\u30012018.11(\u795e\u6238)<\/li>\n\n\n\n<li>\u5927\u95a2\u745e\u6cbb\u3001\u98ef\u5cf6\u4e00\u98db\u3001\u702c\u5c71\u4f91\u4eae\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u85e4\u679d\u771f\u53f8\u3001\u8352\u6728\u771e\u88d5\u3001\u4e94\u982d\u4e09\u79c0\u3001\u5929\u8c9d\u8ce2\u4e8c. \u80c3\u764c\u306b\u304a\u3051\u308b\u30cb\u30dc\u30eb\u30de\u30d6\u306e\u6709\u52b9\u6027\u3001\u5b89\u5168\u6027\u306e\u691c\u8a0e. \u7b2c 60 \u56de\u65e5\u672c\u6d88\u5316\u5668\u75c5\u5b66\u4f1a\u5927\u4f1a\u30012018.11(\u795e\u6238)<\/li>\n\n\n\n<li>\u98ef\u5cf6\u4e00\u98db\u3001\u6c60\u7530\u4f73\u7e54\u3001\u5927\u95a2\u745e\u6cbb\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u85e4\u679d\u771f\u53f8\u3001\u4e94\u982d \u4e09\u79c0\u3001\u8352\u6728\u771e\u88d5\u3001\u5929\u8c9d\u8ce2\u4e8c. \u539f\u767a\u6027\u5c0f\u8178\u764c\u306b\u5bfe\u3057 Nivolumab \u306e\u6709\u52b9\u6027\u304c\u793a\u5506\u3055\u308c\u305f 1 \u4f8b. \u7b2c 353 \u56de\u65e5\u672c\u6d88\u5316\u5668\u75c5\u5b66\u4f1a\u95a2\u6771\u652f\u90e8\u4f8b\u4f1a\u30012019.2(\u6771\u4eac)<\/li>\n\n\n\n<li>\u4e2d\u6751\u660c\u592a\u90ce\u3001\u52a0\u85e4\u5143\u55e3\u3001\u5929\u8c9d\u8ce2\u4e8c. H.pylori \u9670\u6027\/\u9664\u83cc\u62b5\u6297\u6027 MALT \u30ea\u30f3\u30d1\u816b\u306b\u5bfe\u3059\u308b\u9ad8\u7528\u91cf\u30af\u30e9\u30ea\u30b9\u30ed\u30de\u30a4\u30b7\u30f3\u5358\u5264\u7642\u6cd5. \u7b2c 16 \u56de\u65e5\u672c\u6d88\u5316\u7ba1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012019.2(\u59eb\u8def)<\/li>\n\n\n\n<li>\u897f\u5ddd\u548c\u5b8f\u3001\u8a2d\u6a02\u7d18\u5e73\u3001\u5929\u8c9d\u8ce2\u4e8c. ASCO\u3001ESMO\u3001DDW update \u5207\u9664\u4e0d\u80fd\u9032\u884c\u518d\u767a\u80c3\u764c\u306b\u5bfe\u3059\u308bTrifluridine\/Tipiracil \u306e\u56fd\u969b\u5171\u540c\u8a66\u9a13 TAGS(ASCO, ESMO, DDW update TAGS: Phase 3 of<br>trifluridine\/tipiracil in patients with heavily pretreated advanced gastric cancer). \u7b2c 91 \u56de\u65e5\u672c\u80c3\u764c\u5b66\u4f1a\u7dcf\u30012019.2(\u6cbc\u6d25)<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u8b1b\u6f14\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u8352\u6728\u771e\u88d5. HBV\u30fbHCV \u91cd\u611f\u67d3\u8005\u306e DAA \u6cbb\u7642\u306e 1 \u4f8b. \u8328\u57ce\u770c B \u578b\u809d\u708e\u5b66\u8853\u8b1b\u6f14\u4f1a\u30012018.5(\u6c34\u6238)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. C \u578b\u809d\u708e\u6cbb\u7642\u306b\u304a\u3051\u308b DAA \u7642\u6cd5\u306e\u73fe\u72b6\u3068\u8ab2\u984c \u8328\u57ce\u770c\u7248. \u5ea7\u8ac7\u4f1a\u30012018.5(\u3064\u304f\u3070)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. \u5f53\u9662\u306e\u809d\u7d30\u80de\u764c\u3078\u306e\u5206\u5b50\u6a19\u7684\u85ac\u6cbb\u7642 \uff5e\u85ac\u5264\u5e2b\u5916\u6765\u306e\u5f79\u5272\uff5e. \u30ec\u30f3\u30d0\u30c1\u30cb\u30d6\u9069\u5fdc\u8ffd\u52a0\u8b1b\u6f14\u4f1a\u30012018.9(\u3064\u304f\u3070)<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c. \u4e2d\u5b66\u751f\u304b\u3089\u8003\u3048\u308b\u304c\u3093\u306e\u4e88\u9632. \u7b20\u9593\u5e02\u7acb\u53cb\u90e8\u4e2d\u5b66\u6821\u304c\u3093\u4e88\u9632\u6559\u80b2\u8b1b\u6f14\u4f1a\u30012018.7(\u7b20\u9593)<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c. \u304c\u3093\u306a\u3093\u3066\u95a2\u4fc2\u306a\u3044\uff1f\uff5e\u9ad8\u6821\u751f\u306e\u3068\u304d\u306b\u77e5\u3063\u3066\u304a\u304d\u305f\u304b\u3063\u305f\u3053\u3068\uff5e. \u8328\u57ce\u770c\u7acb\u90a3\u73c2\u6e4a\u9ad8\u7b49\u5b66\u6821\u304c\u3093\u6559\u80b2\u8b1b\u8a71\u30012018.11(\u3072\u305f\u3061\u306a\u304b)<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c. \u5927\u8178\u304c\u3093\u5316\u5b66\u7642\u6cd5\u306e\u73fe\u72b6\u3068\u5c55\u671b. \u770c\u592e\u304c\u3093\u5c02\u9580\u30fb\u8a8d\u5b9a\u85ac\u5264\u5e2b\u30bb\u30df\u30ca\u30fc\u30012019.2(\u6c34\u6238)<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u5e73\u621029\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u539f\u8457\u8ad6\u6587\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, Ueda S, Yoshida K, Shimodaira H, Nishina T, Tsuda M, Kurokawa Y, Tamura T, Sasaki Y, Morita S, Koizumi W. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, noninferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2(4):277-287, 2017<\/li>\n\n\n\n<li>Nishikawa K, Yamada Y, Ishido K, Gotoh M, Bando H, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin. Gastric Cancer. 20(4):640-645, 2017<\/li>\n\n\n\n<li>Osaki T, Mabe K, Zaman C, Yonezawa H, Okuda M, Amagai K, Fujieda S, Goto M, Shibata W, Kato M, Kamiya S. Usefulness of detection of clarithromycin-resistant Helicobacter pylori from fecal specimens for young adults treated with eradication therapy. Helicobacter. 22(5), 2017<\/li>\n\n\n\n<li>\u4f0a\u6771\u5b8c\u3001\u8352\u6728\u771e\u88d5. Klebsiella pneumoniae \u306b\u3088\u308b\u809d\u81bf\u760d\u3068\u4ed6\u8d77\u56e0\u83cc\u306b\u3088\u308b\u809d\u81bf\u760d\u306e\u5dee\u7570\u306b\u3064\u3044\u3066. \u8328\u57ce\u770c\u75c5 \u533b\u8a8c 34(2): 15-20, 2018<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u4f50\u85e4\u96c5\u5fd7\u3001\u91d1\u5b50\u525b\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u6e9d\u4e0a\u88d5\u58eb. \u6d88\u5316\u7ba1\u816b\u760d\u5185\u8996\u93e1\u6cbb\u7642\u306b\u5bfe\u3059\u308b\u5916\u79d1\u30fb\u5185\u79d1 \u8a3a\u7642\u79d1\u3092\u307e\u305f\u3044\u3060\u5354 \u8abf\u8a3a\u7642 CRT \u5f8c\u5c40\u6240\u518d\u767a\u30d0\u30ec\u30c3\u30c8\u817a\u764c\u306b\u30ec\u30b6\u30d5\u30a3\u30ea\u30f3 PDT \u3092\u65bd\u884c\u3057\u305f\u4e00\u4f8b. \u7b2c104 \u56de \u65e5\u672c\u6d88\u5316\u5668\u5185\u8996\u93e1 \u5b66\u4f1a\u95a2\u6771\u652f\u90e8\u4f8b\u4f1a 2017.6 (\u6771\u4eac)<\/li>\n\n\n\n<li>\u5927\u95a2\u745e\u6cbb\u3001\u4e94\u982d\u4e09\u79c0\u3001\u5c0f\u677e\u7fa9\u5e0c\u3001\u52a0\u85e4\u590f\u6a39\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u85e4\u679d\u771f\u53f8\u3001\u8352\u6728\u771e\u88d5\u3001\u5929\u8c9d\u8ce2\u4e8c \u51fa\u8840\u6027\u5341\u4e8c\u6307\u8178\u6f70\u760d\u306b\u5bfe\u3059\u308b\u5185\u8996\u93e1\u7684\u6b62\u8840\u6cd5\u306e\u691c\u8a0e. \u7b2c 94 \u56de\u65e5\u672c\u6d88\u5316\u5668\u5185\u8996\u93e1\u5b66\u4f1a \u7dcf\u4f1a\u30012017.10 (\u798f\u5ca1)<\/li>\n\n\n\n<li>\u5c71\u5ca1\u6b63\u6cbb\u3001\u4e94\u982d\u4e09\u79c0\u3001\u85e4\u679d\u771f\u53f8\u3001\u5c0f\u677e\u7fa9\u5e0c\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u5927\u95a2\u745e\u6cbb\u3001\u8352\u6728\u771e\u88d5\u3001\u5929\u8c9d\u8ce2\u4e8c. \u80c3\u9759\u8108\u7624 \u7834\u88c2\u306b\u5bfe\u3057 Cyanoacrylate \u307e\u305f\u306f EVL \u3067\u6b62\u8840\u8853\u3092\u8a66\u307f\u305f 65 \u4f8b\u306e\u691c\u8a0e. \u7b2c 94\u56de\u65e5\u672c\u6d88\u5316\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u7dcf \u4f1a\u30012017.10 (\u798f\u5ca1)<\/li>\n\n\n\n<li>\u85e4\u679d\u771f\u53f8\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u8352\u6728\u771e\u88d5\u3001\u4e94\u982d\u4e09\u79c0\u3001\u5927\u95a2\u745e\u6cbb\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u77f3\u6a4b\u8087\u3001\u52a0\u85e4\u590f\u6a39\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u5c0f\u677e\u7fa9\u5e0c. \u5f53\u9662\u306b\u304a\u3051\u308b\u80c3\u764c\u306b\u5bfe\u3059\u308b\u5341\u4e8c\u6307\u8178\u30b9\u30c6\u30f3\u30c8\u306e\u52b9\u679c\u3068\u554f\u984c\u70b9. \u7b2c 59 \u56de\u65e5\u672c\u6d88\u5316\u5668\u75c5\u5b66\u4f1a\u5927\u4f1a\u30012017.10 (\u798f \u5ca1)<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c\u3001\u5c0f\u677e\u7fa9\u5e0c\u3001\u52a0\u85e4\u590f\u6a39\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u5927\u95a2\u745e\u6cbb\u3001 \u85e4\u679d\u771f\u53f8\u3001\u8352\u6728\u771e\u88d5\u3001\u4e94\u982d\u4e09\u79c0. \u6a19\u6e96\u6cbb\u7642\u4e0d\u5fdc\u30fb\u4e0d\u8010\u75c7\u4f8b\u306e\u30d8\u30ea\u30b3\u30d0\u30af\u30bf\u30fc\u30fb\u30d4\u30ed\u30ea(Hp)\u9664\u83cc\u6cbb\u7642. \u7b2c 59 \u56de\u65e5\u672c\u6d88\u5316\u5668\u75c5\u5b66\u4f1a\u5927\u4f1a\u30012017.10 (\u798f\u5ca1)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5\u3001\u85e4\u679d\u771f\u53f8\u3001\u5927\u95a2\u745e\u6cbb\u3001\u5c71\u5ca1\u6b63\u6cbb. \u5f53\u9662\u306e C \u578b\u809d\u708e\u7d4c\u53e3\u5264\u6cbb\u7642\u306b\u304a\u3051\u308b M2BPGi \u5024\u306e\u63a8\u79fb. \u7b2c 21 \u56de\u65e5\u672c\u809d\u81d3\u5b66\u4f1a\u5927\u4f1a, 2017.10 (\u798f\u5ca1)<\/li>\n\n\n\n<li>\u5ca9\u6c38\u4e00\u90ce \u3001\u5929\u8c9d\u8ce2\u4e8c \u3001\u5c0f\u677e\u5609\u4eba \u3001\u4ed6 . TRICOLORE \u5207 \u9664 \u4e0d \u80fd \u5927 \u8178 \u764c \u306b \u5bfe \u3059 \u308b<br>mFOLFOX6\/CapeOX+Bev \u3068 S-1\/CPT-11+Bev \u3068\u306e\u7b2c 3 \u76f8\u8a66\u9a13. \u7b2c 55 \u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a 2017.10(\u6a2a\u6d5c)<\/li>\n\n\n\n<li>\u68ee\u8107\u4fca\u548c\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u5175\u982d\u4e00\u4e4b\u4ecb\u3001\u4ed6. \u9ad8\u9f62\u5927\u8178\u764c\u60a3\u8005\u306b\u304a\u3051\u308b UFT\/LV+\u30d9\u30d0\u30b7\u30ba\u30de\u30d6\u306e\u52b9\u679c\u5b89\u5168\u6027\u306b\u5bfe\u3059 \u308b\u5e74\u9f62\u306e\u5f71\u97ff. \u7b2c 55 \u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a 2017.10(\u6a2a\u6d5c)<\/li>\n\n\n\n<li>\u98ef\u5cf6\u4e00\u98db\u3001\u5927\u95a2\u745e\u6cbb\u3001\u702c\u5c71\u4f91\u4eae\u3001\u672c\u591a\u5bdb\u4e4b\u3001\u77f3\u6a4b\u8087\u3001\u5c71\u5ca1\u6b63\u6cbb\u3001\u85e4\u679d\u771f\u53f8\u3001 \u4e94\u982d\u4e09\u79c0\u3001\u8352\u6728\u771e\u88d5\u3001\u5929\u8c9d\u8ce2\u4e8c\u3001\u5800\u5ddd\u8aed\u3001\u7a32\u8449\u5eb7\u8a18\u3001\u5c0f\u570b\u82f1\u4e00. \u81b5\u81d3\u764c\u8853\u5f8c\u306b Trousseau \u75c7\u5019\u7fa4\u3092\u767a\u75c7\u3057\u6cbb\u7642\u306b\u96e3\u6e0b\u3057\u305f\u4e00\u4f8b. \u7b2c 348 \u56de\u65e5\u672c\u6d88\u5316\u5668\u75c5\u5b66\u4f1a\u95a2\u6771\u652f\u90e8\u4f8b\u4f1a 2018.2(\u6771\u4eac)<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u8b1b\u6f14\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u8352\u6728\u771e\u88d5. C \u578b\u809d\u708e\u30fbB \u578b\u809d\u708e\u306b\u5bfe\u3059\u308b\u65b0\u85ac\u306e\u52b9\u679c\u3068\u73fe\u72b6. \u7b20\u9593\u5e02\u533b\u5e2b\u4f1a\u80f8\u90e8\u75be\u60a3\u691c\u8a0e\u4f1a\u30012017.6 (\u7b20\u9593)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. C \u578b\u809d\u708e\u306e\u6700\u65b0\u6cbb\u7642. \u30a2\u30eb\u30d5\u30ec\u30c3\u30b5 MS \u5b66\u8853\u8b1b\u6f14\u4f1a\u3001 2017.6 (\u6c34\u6238)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. \u5185\u8996\u93e1\u30bb\u30f3\u30bf\u30fc\u306e\u3054\u6848\u5185. \u5730\u57df\u533b\u7642\u9023\u643a\u63a8\u9032\u61c7\u8ac7\u4f1a\u8b1b\u6f14\u4f1a\u30012017.11\uff08\u7b20\u9593\uff09<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c. Initial Capecitabin + Bevacizumab \u7642\u6cd5. \u8328\u57ce\u770c\u6d88\u5316\u5668\u304c\u3093\u30d5\u30a9\u30fc\u30e9\u30e0\u30012017.11 (\u3064\u304f\u3070) \u4e94\u982d\u4e09\u79c0. \u708e\u75c7\u6027\u8178\u75be\u60a3\u306e\u8a3a\u65ad\u3068\u6cbb\u7642 \u2015\u85ac\u7269\u7642\u6cd5\u3092\u4e2d\u5fc3\u306b\u2015. \u6c34\u6238\u85ac\u5264\u5e2b\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\u3001<br>2018.1 (\u6c34\u6238)<\/li>\n\n\n\n<li>\u4e94\u982d\u4e09\u79c0. \u5927\u8178\u304c\u3093\u201c\u65e9\u304f\u898b\u3064\u3051\u3066\u6cbb\u3057\u307e\u3057\u3087\u3046!!\u201d. \u7b2c 22 \u56de\u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u516c\u958b\u8b1b\u5ea7\u30012018.2 (\u7b20\u9593)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. \u5f53\u9662\u306e\u809d\u764c\u8a3a\u7642\u306e\u73fe\u6cc1. \u7b2c 32 \u56de\u770c\u5357\u30fb\u770c\u897f\u809d\u75be\u60a3\u7814\u7a76\u4f1a \u6559\u80b2\u8b1b\u6f14 2018.2 (\u3064\u304f\u3070)<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5. \u5f53\u9662\u306b\u304a\u3051\u308b\u30ea\u30d5\u30ad\u30b7\u30de\u9320\u306e\u4f7f\u7528\u7d4c\u9a13\u306b\u3064\u3044\u3066. \u8328\u57ce\u770c\u30ea\u30d5\u30ad\u30b7\u30de\u9320\u767a\u58f2\u4e00\u5468\u5e74\u8a18\u5ff5\u8b1b\u6f14\u4f1a\u30012018.3 (\u6c34\u6238)<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u305d\u306e\u4ed6\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u8352\u6728\u771e\u88d5. \u8102\u80aa\u809d\u3068\u9ad8\u4e2d\u6027\u8102\u80aa\u8840\u75c7. \u5ea7\u8ac7\u4f1a\u300c\u9ad8\u4e2d\u6027\u8102\u80aa\u8840\u75c7\u306e\u6cbb\u7642\u610f\u7fa9\u3092\u8003\u3048\u308b-SPPARM\u03b1\u306e\u53ef\u80fd\u6027\u300d. 2018.2 (\u6c34\u6238)<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u5e73\u621028\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Nishi T, Hamamoto Y , Nagase M , Denda T , Yamaguchi K , Amagai K ,Miyata Y, Yamanaka Y ,Yanai K , Ishikawa T , Kuroki Y , Fujii H . PhaseII trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer ( TOPIC study ) . Oncol Lett11 ( 6 ) : 4049-4054 ,2016<\/li>\n\n\n\n<li>Sasaki Y, Akasu T, Saito N, Kojima H, Matsuda K, Nakamori S, Komori K ,Amagai K , Yama guchi T, Ohue M, Nagashima K , Yamada Y . Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage \u2162 colorectal cancer . Cancer Sci 107 ( 7 ) : 10 06 &#8211; 1012 , 2016<\/li>\n\n\n\n<li>Nishina T, Boku N, Gotoh M, Shimada Y, Hamamoto Y, Yasui H ,Yamaguchi K, Kawai H , Nakayama N, Amagai K, Mizusawa J , Nakamura K ,Shirao K, Ohtsu A. Randomized phase \u2161 study of second -line chemotherapy with the best available5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens ( JCOG0407 ) . Gastric Cancer 1 9 ( 3 ) : 902-910 ,2016<\/li>\n\n\n\n<li>Bando H, Yamada Y, Tanabe S, Nishikawa K, Gotoh M, Sugimoto N, Nishina T, Amagai K , Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H Hamada C, Hyodo I . Efficacy and safety of S -1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer .  Gastric Cancer 19 ( 3 ) : 919 -926 , 2016<\/li>\n\n\n\n<li>Hamada C, Yamada Y, Azuma M, Nishikawa K, Gotoh M, Bando H, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hyodo I . Meta &#8211; analysis supporting no ninferiority of oxaliplatin plus S &#8211; 1 to cisplatin plus S &#8211; 1 in first-line treatment of advanced gastric cancer ( G -SOX study ) : indirect comparison with S &#8211; 1 alone . Int J Clin Oncol 21 ( 4 ) : 66 8 -675 , 2016<\/li>\n\n\n\n<li>Nishina T, Moriwaki T, Shimada M, Higashijima J , Sakai Y, Masuishi T, Ozeki M, Amagai K, Negoro Y, Indo S, Denda T, Sato M, Yamamoto Y, Nakajima G, Mizuta M, Takahashi I, Hiroshima Y, Ishida H, Maeba T, Hyodo I . Uracil-Tegafur and oral Leucovorin combined with Bevacizumab in elderly patients ( A ged \u2267 75 Years ) with metastatic colorectal cancer : A Multicenter, Phase \u2161Trial ( Joint study of Bevacizumab, oral eucovorin, and Uracil-Tegafur in elderly patients [ J-BLUE ] Study ) . Cl in Colorectal Cancer 15 ( 3 ) : 236-242 ,2016<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u8352\u6728\u771e\u88d5 . \u5f53 \u9662 \u3067 \u306e M2 BP G i \u691c \u67fb \uff5e \u30a6 \u30a4 \u30eb \u30b9 \u809d \u708e \u3092 \u4e2d \u5fc3 \u306b \uff5e . \u7b2c 3 \u56deM2 BP G i \u7814 \u7a76 \u4f1a \u3001 2 0 1 6 .9 (\u3064\u304f\u3070 )<\/li>\n\n\n\n<li>\u5929 \u8c9d \u8ce2 \u4e8c \u3001 \u798f \u5cf6 \u4eae \u6cbb \u3001 \u77f3 \u795e \u6d69 \u5fb3 \u3001 \u85e4 \u539f \u7fa9 \u4e4b \u3001 \u68a8 \u672c \u7be4 \u3001 \u85ea \u5d0e \u88d5 \u3001 \u4eca \u672c \u6cbb\u5f66 \u3001 \u4eca \u91ce \u5143 \u535a \u3001 \u5c0f \u5bfa \u6cf0 \u5f18 \u3001 \u4e0a \u4e4b \u5712 \u82b3 \u4e00 \u3001 \u9580 \u8107 \u91cd \u61b2 \u3001 \u4e09 \u8f2a \u6d0b \u4eba \u3001 \u5c71 \u53e3 \u62d3 \u6d0b \u3001\u5c71 \u53e3 \u535a \u7d00 \u3001 \u5317 \u5c71 \u4e08 \u4e8c \uff0e \u80c3 \u304c \u3093 \u306b \u5bfe \u3059 \u308b \u8179 \u8154 \u5185 \u5316 \u5b66 \u7642 \u6cd5 \u306e \u52b9 \u679c \u8179 \u819c \u64ad \u7a2e \u967d\u6027 \u80c3 \u764c \u306b \u5bfe \u3059 \u308b \u30d1 \u30af \u30ea \u30bf \u30ad \u30bb \u30eb \u8179 \u8154 \u5185 \u6295 \u4e0e \u4f75 \u7528 \u7642 \u6cd5 \u3092 \u691c \u8a3c \u3059 \u308b \u7b2c III \u76f8 \u81e8\u5e8a\u8a66\u9a13 . \u8179 \u8154 \u5185 \u5316 \u5b66 \u7642 \u6cd5 \u7814 \u7a76 \u4f1a \u3001 \u7b2c 5 4 \u56de \u65e5 \u672c \u764c \u6cbb \u7642 \u5b66 \u4f1a \u5b66 \u8853 \u96c6 \u4f1a \u30012 0 1 6 .1 0 (\u6a2a \u6d5c )<\/li>\n\n\n\n<li>\u5929 \u8c9d \u8ce2 \u4e8c \u3001 \u4e2d \u5c71 \u6607 \u5178 \u3001 \u8a2d \u697d \u7d18 \u5e73 \u3001 \u9ad8 \u5cf6 \u6df3 \u751f \u3001 \u85e4 \u8c37 \u548c \u6b63 \u3001 \u80a5 \u7530 \u572d \u4ecb \u3001 \u539f \u6d69 \u6a39 \u3001 \u5ee3 \u4e2d \u79c0 \u4e00 \u3001 \u897f \u5ddd \u548c \u5b8f \u3001 \u6728 \u6751 \u8c4a \u3001 \u5409 \u7530 \u548c \u5f18 \u3001 \u660e \u77f3 \u96c4 \u7b56 \u3001 \u4e0b \u5e73 \u79c0 \u6a39 \u3001 \u4ec1 \u79d1 \u667a \u88d5 \u3001 \u5c0f \u6cc9 \u548c \u4e09 \u90ce \uff0e \u80c3 \u304c \u3093 \u306b \u304a\u3051\u308b 2 \u6b21 \u5316 \u5b66 \u7642 \u6cd5 \u306e \u5c55 \u671b \u80c3 \u764c \u306e \u4e8c \u6b21 \u6cbb \u7642\u306b\u304a\u3051\u308b na b-P T X ( w e ek l y \/ q3 w) \u3068 week l y PT X \u3068\u306e\u7b2c 3 \u76f8 \u6bd4 \u8f03 \u8a66 \u9a13( A B SO L U T E ) . \u7b2c 5 4 \u56de \u65e5 \u672c \u764c \u6cbb \u7642 \u5b66 \u4f1a \u5b66 \u8853 \u96c6 \u4f1a \u3001 2 0 1 6 .1 0 (\u6a2a \u6d5c )<\/li>\n\n\n\n<li>\u5929 \u8c9d \u8ce2 \u4e8c \u3001 \u9060 \u85e4 \u58ee \u767b \u3001 \u5c71 \u5ca1 \u6b63 \u6cbb \u3001 \u5927 \u95a2 \u745e \u6cbb \u3001 \u85e4 \u679d \u771f \u53f8 \u3001 \u8352 \u6728 \u771e \u88d5 \u3001 \u4e94 \u982d \u4e09\u79c0 \uff0e \u30dc \u30ce \u30d7 \u30e9 \u30b6 \u30f3 \u3092 \u7528 \u3044 \u305f H .py l or i \u9664 \u83cc \u6cbb \u7642 \u306e \u6709 \u7528 \u6027 . \u7b2c 5 8 \u56de\u65e5\u672c\u6d88\u5316\u5668 \u75c5 \u5b66 \u4f1a \u5927 \u4f1a \u3001 2 0 16 .1 1 (\u795e \u6238 )<\/li>\n\n\n\n<li>\u5929 \u8c9d \u8ce2 \u4e8c \u3001 \u5c0f \u6797 \u5927 \u4ecb \u3001 \u77f3 \u795e \u6d69 \u5fb3 \u3001 \u85e4 \u539f \u7fa9 \u4e4b \u3001 \u798f \u5cf6 \u4eae \u6cbb \u3001 \u68a8 \u672c \u7be4 \u3001 \u85ea \u5d0e \u88d5 \u3001\u4eca \u672c \u6cbb \u5f66 \u3001 \u4eca \u91ce \u5143 \u535a \u3001 \u5c0f \u5bfa \u6cf0 \u5f18 \u3001 \u4e0a \u4e4b \u5712 \u82b3 \u4e00 \u3001 \u9580 \u8107 \u91cd \u61b2 \u3001 \u4e09 \u8f2a \u6d0b \u4eba \u3001 \u5c71 \u53e3 \u535a \u7d00 \u3001 \u5c71 \u53e3 \u62d3 \u6d0b \u3001 \u5317 \u5c71 \u4e08 \u4e8c \uff0e \u8179 \u819c \u64ad \u7a2e \u3092 \u4f34 \u3046 \u80c3 \u764c \u306b \u5bfe \u3059 \u308b S-1 + \u30d1 \u30af \u30ea \u30bf\u30ad \u30bb \u30eb \u7d4c \u9759 \u8108 \u30fb \u8179 \u8154 \u5185 \u4f75 \u7528 \u7642 \u6cd5 \/S-1 + \u30b7 \u30b9 \u30d7 \u30e9 \u30c1 \u30f3 \u4f75 \u7528 \u7642 \u6cd5 \u306b \u3088 \u308b \u7b2c III \u76f8 \u81e8 \u5e8a \u8a66 \u9a13 ( PHOENIXG Ctraial ) ( I P PT X plus S -1 \/PT X compared with SP in gastric cancer with peritoneal metastasis : PHOENIX &#8211; GC trial ) . \u7b2c 8 9\u56de \u65e5 \u672c \u80c3 \u764c \u5b66 \u4f1a \u7dcf \u4f1a \u3001 2 0 1 7 .3 (\u5e83 \u5cf6)<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u8b1b\u6f14\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u5929\u8c9d\u8ce2\u4e8c . \u6d88 \u5316 \u5668 \u764c \u5316 \u5b66 \u7642 \u6cd5 \u306e U p-t o -da t e . \u7b2c 23 \u56de \u6771 \u5317 \u81e8 \u5e8a \u816b \u760d \u30bb \u30df \u30ca \u30fc \u3001 2 0 1 6 . 6 (\u4ed9 \u53f0 )<\/li>\n\n\n\n<li>\u5929\u8c9d\u8ce2\u4e8c . \u5927 \u8178 \u764c \u6cbb \u7642 \u306e \u6700 \u65b0 \u30a8 \u30d3 \u30c7 \u30f3 \u30b9 \u3068 \u5c06 \u6765 \u306e \u5c55 \u671b . \u53e4 \u6cb3 \u5730 \u533a \u304c \u3093 \u6cbb \u7642 \u30bb \u30df \u30ca \u30fc \u3001 2 0 1 6 . 6 (\u53e4 \u6cb3 ) <\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5 . \u514d \u75ab \u6291 \u5236 \u4e0b \u306b \u304a \u3051 \u308b H BV \u518d \u6d3b \u6027 \u5316 \u5bfe \u7b56 \u30ac \u30a4 \u30c9 \u30e9 \u30a4 \u30f3 \u306e \u89e3 \u8aac . \u7b2c 27 \u56de \u8328 \u57ce \u770c \u304c \u3093 \u8a3a \u7642 \u9023 \u643a \u62e0 \u70b9 \u75c5 \u9662 \u7814 \u4fee \u4f1a \u3001 2 0 1 6 .6 (\u7b20 \u9593 ) <\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5 . \u514d \u75ab \u6291 \u5236 \u30fb \u5316 \u5b66 \u7642 \u6cd5 \u306b \u3088 \u308a \u767a \u75c7 \u3059 \u308b B \u578b \u809d \u708e \u5bfe \u7b56 &lt; \u30e9 \u30f3 \u30c1 \u30e7 \u30f3 \u30bb \u30df \u30ca \u30fc &gt;. \u7b2c 17 \u56de \u65e5 \u672c \u533b \u7642 \u30de \u30cd \u30b8 \u30e1 \u30f3 \u30c8 \u5b66 \u4f1a \u8328 \u57ce \u770c \u652f \u90e8 \u5b66 \u8853 \u96c6 \u4f1a \u3001 2 0 1 6 .9 (\u6c34 \u6238 )<\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5 . \u5f53 \u9662 \u306b \u304a \u3051 \u308b \u30a8 \u30eb \u30ab \u30eb \u30c1 \u30f3 \u306e \u6295 \u4e0e \u5b9f \u614b . Liver Forum in MITO\u3001 2 0 1 6 .1 1 (\u6c34\u6238) <\/li>\n\n\n\n<li>\u8352\u6728\u771e\u88d5 . \u5f53 \u9662 \u3067 \u306e C \u578b \u809d \u708e \u7d4c \u53e3 \u5264 \u6cbb \u7642 \u306e \u73fe \u6cc1 . \u8328 \u57ce \u770c \u592e \u5730 \u533a \u809d \u708e \u30bb \u30df \u30ca\u30fc\u30012 0 1 7 .1 (\u6c34\u6238)<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u305d\u306e\u4ed6\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u8352\u6728\u771e\u88d5 . C \u578b \u809d \u708e \u53d7 \u8a3a \u30fb \u53d7 \u7642 \u5553 \u767a \u756a \u7d44 \u300c \u7b11 \u9854 \u306e \u6bce \u65e5 \u3092 \u9001 \u308b \u305f \u3081 \u306b \uff5e \u65e9\u304f \u898b \u3064 \u3051 \u3066 \u3001 \u96a0 \u308c \u305f \u75c5 \u6c17 C \u578b \u809d \u708e \uff5e \u300d \u3001 2 0 1 7 .2 ( \u30b8 \u30a7 \u30a4 \u30b3 \u30e0 \u8328 \u57ce )<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>\u5e73\u621028\u5e74\u5ea6\uff5e\u4ee4\u548c6\u5e74\u5ea6 \u4ee4\u548c6\u5e74\u5ea6 \u3010\u8ad6\u6587\u3011 \u3010\u5b66\u4f1a\u767a\u8868\u3011 \u3010\u8b1b\u6f14\u3011 \u4ee4\u548c5\u5e74\u5ea6 \u3010\u8457\u66f8\u3011 \u4ee4\u548c4\u5e74\u5ea6 \u3010\u8ad6\u6587\u3011 \u3010\u5b66\u4f1a\u767a\u8868\u3011 \u3010\u8b1b\u6f14\u3011 \u4ee4\u548c3\u5e74\u5ea6 \u3010\u8ad6\u6587\u3011 \u3010\u5b66\u4f1a\u767a\u8868\u3011 \u3010\u8b1b\u6f14\u3011 \u4ee4\u548c2\u5e74\u5ea6 \u3010\u8ad6\u6587\u3011 \u3010\u5b66\u4f1a\u767a\u8868\u3011 [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":730,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","vk-ltc-link":"","vk-ltc-target":"0"},"class_list":["post-16578","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/16578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/comments?post=16578"}],"version-history":[{"count":4,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/16578\/revisions"}],"predecessor-version":[{"id":25081,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/16578\/revisions\/25081"}],"up":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/730"}],"wp:attachment":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/media?parent=16578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}